AUSTRALIA
Clayton - Monash University
Peter David Currie PhD

RG  Using zebrafish congenital muscular dystrophy models to find novel therapies.
$100,000.00  8/1/2016  7/31/2017  Year 2
$100,000.00  8/1/2017  7/31/2018  Year 3

Summary Numerous studies have suggested that zebrafish genetic models of human diseases can recapitulate many aspects of the human pathology. This is particularly well documented for muscle wasting diseases where a number of genetic models of human muscular dystrophies have been identified by our laboratory. Specific to the aims of this project was the identification of a zebrafish mutation in the Laminin alpha 2 gene which is mutated in the most common form of congenital muscular dystrophy (CMD). We have used this zebrafish model to make observations on the mechanisms by why muscle cells die when they lack Laminin alpha2 protein. We now wish to understand this process better and will use the specific advantages of the zebrafish system to make observations that will lead to the identification of novel therapeutic approaches for the treatment of CMD. We have also developed methods to screen the zebrafish model of CMD to identify novel drug compounds and we will use these methods to find drugs that prevent the onset and progression of muscle wasting in this model. We hope these compounds will form the basis for the development of drugs to treat congenital muscular dystrophy.

Tamar Esther Sztal Ph.D

DG15  Evaluating therapies to improve muscle function in nemaline myopathy

$60,000.00  2/1/2016  1/31/2017  Year 1
$60,000.00  2/1/2017  1/31/2018  Year 2
$60,000.00  2/1/2018  1/31/2019  Year 3

Summary Nemaline myopathies are congenital muscle diseases causing severe muscle weakness and low muscle tone. Typically patients exhibit skeletal muscle weakness and feeding difficulties in infancy, however, severe cases result in death at or before birth. The skeletal muscle weakness is non-progressive with survival to 30 years exceeding 80%. Therefore these patients suffer from muscle weakness and associated problems, such as respiratory insufficiency, throughout their life. There is no effective therapy for nemaline myopathy however many patients are self-administering supplements including tyrosine, following only anecdotal reports of their benefit. To screen for effective new therapies I have created zebrafish nemaline myopathy models caused by mutations in ACTA1 or NEB, accounting for 75% of severe cases. I have shown that these models accurately recreate the disease with fish containing nemaline bodies in their skeletal muscle and demonstrating decreased muscle function. Using the advantages of the zebrafish system for high-throughput chemical screening, I aim to identify effective novel therapies that are directly translatable to patients. I will evaluate existing compounds to determine their effect, if any, and to establish a baseline for new therapies to surpass. I will then test more than 1200 drugs to find the most effective at increasing muscle function and reducing disease severity.

Crawley - The University of Western Australia
Miranda Grounds Ph.D

RG16  Why does lipid accumulate in dysferlin-deficient muscles?

$95,370.00  8/1/2016  7/31/2017  Year 1
$97,769.00  8/1/2017  7/31/2018  Year 2

Summary Dysferlinopathies are a form of muscular dystrophy that is caused by defects in the gene that makes a protein called dysferlin. Dysferlinopathies occur in humans, and in mice and zebrafish that are useful experimental models to study this disease. The reasons why progressive muscle weakness occurs in young adult humans are not clear and there is no effective treatment. We have shown that the dysferlin-deficient muscles contain many droplets of lipid (fat) within the muscle cells, and that fat cells (called adipocytes) replace the muscle cells over time. This will impair function and result in muscle wasting. This project investigates the molecular mechanisms for these striking lipid related changes. Aim 1 will describe how the key aspects of lipid metabolism are altered within dysferlin-deficient muscles. Aim 2 will examine dysferlin-deficient (and normal) muscle cells and adipocytes in tissue culture to test their lipogenic capacity, and cross-talk between combinations of these cells and their secreted products. Finally, in vivo studies in mice in Aim 3, will determine if the adverse clinical effects of glucocorticoids on dysferlinopathies is due to their capacity to enhance lipogenesis and adipogenesis. These combined studies will provide insight into the
mechanisms that lead to the dystropathology in dysferlin-deficient muscles. This research aims to identify the best targets for therapy and accelerate future targeted drug therapy trials for dysferlinopathies.

**Nigel George Laing Ph.D.**

**RG16**  
Evaluating gene therapy for McArdle's disease using a mouse model  
$99,206.00$  
2/1/2017  
1/31/2018  
Year 1  
$50,206.00$  
2/1/2018  
1/31/2019  
Year 2  

**Summary**  
McArdle disease is caused by when an important muscle enzyme that is required to break down muscle energy stores is missing. The disease causes muscle pain when exercising, and in severe cases, muscle weakness/wasting occurs and can limit daily activity. There is currently no cure for McArdle disease. We will use a mouse model with McArdle disease to test two potential treatment methods. Both methods will use a modified version of virus to deliver crucial genetic material. For the first method will deliver a normal version of the missing enzyme. Although very logical, this approach is likely to cause an immune reaction as the body of a McArdle disease mouse (or a human patient) will have never seen this enzyme before. Thus, we will also in a parallel set of experiments promote increase levels of an alternative version of the enzyme. This alternative enzyme is found in adult brain tissue and in foetal muscle, and it has the same function of the missing enzyme in skeletal muscles. We propose that due to this alternative brain version being so similar, it could restore enzyme function in the muscle if it is increased to sufficient quantities. These potential therapeutic strategies will be clinically applicable to patients and may also be applied to other muscle diseases.

**Sydney - The University of Sydney**

**Michael L.H. Huang Ph.D.**

**DG16**  
Targeting Mitochondrial Homeostasis in the Pathogenesis of Friedreich’s Ataxia  
$59,000.00$  
8/1/2016  
7/31/2017  
Year 1  
$58,100.00$  
8/1/2017  
7/31/2018  
Year 2  
$60,000.00$  
8/1/2018  
7/31/2019  
Year 3  

**Summary**  
Friedreich’s ataxia (FA) is a devastating neuro- and cardio-degenerative condition caused by a lack of a mitochondrial protein, frataxin. My interest in FA developed while being mentored by an established research program that has held continuous research funding from MDA USA since 2001. My research has resulted in 22 publications in the last 5 years, including 3 articles in PNAS (2 as 1st or equal-1st author). My studies identified mitochondrial defects in tissues lacking frataxin, leading to FA pathogenesis. As the heart and the nervous system rely heavily on mitochondria to fulfill their energy demands, they are most affected by its dysfunction. Thus, I will examine the extent that frataxin-deficiency disrupts mitochondrial homeostasis and the possibility of targeting this process as a therapy. Mitochondria constantly undergo fusion or division according to energy demands. As previous studies have shown proliferation of damaged mitochondria in frataxin-deficient cells, I will explore alterations in the ability for mitochondria to fuse or divide in our animal models of FA. Further, I will assess the pathological changes in the synthesis and maintenance of mitochondria in FA. Importantly, based on results in my first author article in the Am. J. Pathol. 2013;183:745-57, I will investigate the mechanism of how vitamin B3 can boost mitochondrial health to prevent the pathology in FA through its ability to affect mitochondrial dynamics, biogenesis and clearance.

**BRAZIL**

**São Paulo - Fundacao Faculdade de Medicina**

**Natassia Vieira Ph.D.**

**DG**  
Jagged1 as a genetic modifier of Dystrophin Deficiency  
$60,000.00$  
8/1/2016  
7/31/2017  
Year 2  
$60,000.00$  
8/1/2017  
7/31/2018  
Year 3  

**Summary**  
Absence of functional dystrophin causes muscle degeneration in DMD, but additional factors involved in the pathogenesis remain poorly understood and represent an unexplored territory for therapy. Among the different animal models for DMD, the most similar to the human condition is the golden retriever muscular dystrophy (GRMD) dog. We identified milder affected GRMD dogs (here called escapers) clinically distinguishable from other affected dogs, despite the absence of muscle dystrophin, no utrophin upregulation and raised serum creatine kinase levels. With 3 independent approaches we found a new modifier gene, Jagged1, which can modulate the phenotype of these GRMD dogs. Jagged1 overexpression also rescues the dystrophic phenotype in the DMD zebrafish model. This candidate gene opens new possibilities for therapeutic approaches for DMD. Aiming to assess the therapeutic potential of Jagged1 we will a) determine the signaling pathways modulated by Jagged1 overexpression and b) evaluate the
functional improvement in the mdx using AAV expression of Jagged1. We will establish mRNA expression profiles of normal and dystrophin-null muscle cells overexpressing Jagged1. This profile will give us new targets that can be used for therapeutic approaches. AAV represents a promising approach to control the expression of genetic modifiers aiming to improve function. The AAV delivery of Jagged1 will determine if transient overexpression improves disease pathology and muscle function.

**CANADA**

**ONTARIO**

**Ottawa - Ottawa Hospital Research Institute**

Michael A. Rudnicki PhD

RG15  Molecular regulation of satellite cell function

$100,000.00  2/1/2016  1/31/2017  Year 1

$100,000.00  2/1/2017  1/31/2018  Year 2

$100,000.00  2/1/2018  1/31/2019  Year 3

**Summary**

Our overarching goal is to facilitate the development of Wnt7a as a protein biologic for the treatment of Duchenne Muscular Dystrophy (DMD). Muscle satellite cells are required for the growth and repair of skeletal muscle. Our laboratory identified a subset of muscle satellite cells that function as stem cells. We have discovered that a secreted protein called Wnt7a stimulates the division of satellite stem cells and also directly stimulates the growth of muscle fibers. Notably, we found that introduction of Wnt7a into normal and dystrophic muscle results in stimulating the growth and function of these muscle stem cells resulting in the formation of increased numbers of myofibers. Here, we have found that dystrophin, the disease gene in DMD, is normally expressed in satellite cells, and its absence alters the function of satellite stem cells. In this application we propose a series of experiments to characterize the nature of the muscle stem cell defect in mdx mice. We will investigate the cell mechanism through which Wnt7a treatment induces an increase of dystrophin-deficient satellite stem cell numbers to stimulate repair of skeletal muscle. Finally, we will assess the utility of Wnt7a as a drug for the treatment of DMD. This work will inform the development of Wnt7a as a therapeutic for the treatment of Duchenne Muscular Dystrophy.

**Toronto - The Hospital for Sick Children**

James Dowling M.D., Ph.D.

RG15  Drug Discovery for RYR1-related myopathies

$100,000.00  2/1/2016  1/31/2017  Year 1

$100,000.00  2/1/2017  1/31/2018  Year 2

$100,000.00  2/1/2018  1/31/2019  Year 3

**Summary**

Myopathies caused by mutation(s) in the type 1 ryanodine receptor (RYR1), termed RYR1-related myopathies, are one of the most common muscle disease groups of childhood. In many cases, RYR1-related myopathies are associated with significant disabilities, including the need for a wheelchair for ambulation, severe spine curvature requiring surgery, and breathing difficulties necessitating the use of a ventilator. In addition, in some children, RYR1 mutations can result in premature death. Currently there are no therapies for these devastating myopathies. In this project, we will identify, develop, and validate new candidate therapeutics for RYR1-related myopathies. We will accomplish this by building on our novel drug development platform, which includes high throughput screening in C. elegans, rapid target validation in the zebrafish, and final testing in patient-derived myotubes. In a preliminary screen, we identified in C. elegans more than 100 possible candidate drugs. Using our proposed research protocol, we will validate and prioritize these novel drug targets using zebrafish and human cell models of the disease. We will also develop new worm and zebrafish models of the disease and screen them for new candidates. The end result will be the identification of drugs suitable for translation to patients, with the ultimate goal being the development of new therapies that will improve the quality and length of life for individuals with RYR1 myopathies.

**QUÉBEC**

**Montreal - Jewish General Hospital/Lady Davis Institute for Medical Research**

Colin Crist Ph.D.

RG  ex vivo expansion of muscle stem cells with regenerative capacity

$100,000.00  8/1/2016  7/31/2017  Year 2

$100,000.00  8/1/2017  7/31/2018  Year 3
Summary

Development of stem cell based therapies, either to modulate the behaviour of, or functionally replace, the pool of endogenous muscle stem cells participating in muscle regeneration, are potential therapeutic strategies for many disorders of skeletal muscle. Replacement of the endogenous pool of muscle stem cells is made difficult in part due to the limited number of donor muscle stem cells available, a problem that is exacerbated by the loss of stem cell behaviour and regenerative capacity when muscle stem cells are expanded ex vivo. Therefore, for stem cell based strategies to be realized as a therapeutic strategy for muscular dystrophies, a greater understanding of the molecular mechanisms governing the activity of muscle stem cells is needed. The long-term objectives of our research program are to further understand molecular mechanisms underlying muscle stem cell capacity to self-renew. We envision manipulating these mechanisms to accelerate stem cell based therapies for muscle disorders. In this proposal, we will enhance skeletal muscle stem cell regenerative capacity by pharmacological manipulation of a pathway regulating protein synthesis in the skeletal muscle stem cell.

Montreal - McGill University

Gary Armstrong Ph.D.

Summary

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disorder affecting motor and in some cases cognitive function. There is a single pharmacological treatment, Riluzole, which has limited therapeutic value. Part of the poor success of Riluzole, and many other clinical trials, can be attributed to our incomplete understanding of the synaptic abnormalities that arise following expression of causative mutations in genes such as superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TARDBP) and Fused in Sarcoma (FUS). In particular, we are lacking information about the earliest ('pre-clinical') events during cellular pathology, such as disruption of neuromuscular transmission, alterations in excitatory and inhibitory interneuron connectivity with motoneurons and changes in intrinsic excitability of motoneurons. We believe that many of these early pathological defects occur as a result of compensatory synaptic homeostatic plastic changes that are operating aberrantly. To investigate this concept I propose to use two model systems (zebrafish and mice). Addressing the questions proposed in brief below will help elucidate the molecular and pathological mechanisms of ALS pathology and complement our clinical trial of Pimozide.

Heather D. Durham Ph.D.

Summary

Amyotrophic lateral sclerosis (ALS) is a complex disease with multiple causes, resulting in fatal loss of motor activity due to dysfunction and death of motor neurons. Multiple genetic mutations are linked to ALS, but the causes of most cases of disease that occur sporadically are unknown. ALS involves complex pathogenic cascades with widespread effects on cellular functions. The challenge is to identify and understand the key elements in those cascades to target for therapy. We have identified disruption of a protein complex that regulates expression of neuronal genes that 'make neurons neurons' and extend processes to connect to other neurons in the network controlling movement. These complexes are called nBAF chromatin remodeling complexes and key proteins of these complexes are lost in motor neurons in familial ALS caused by gene mutations and in sporadic ALS. Thus, we have identified a convergent mechanism that could be targeted to keep motor neurons connected in the network and functioning longer.

Eric Alan Shoubridge Ph.D.

Summary

Mitochondrial dysfunction has been implicated in some familial forms of ALS, but the evidence for mitochondrial involvement has not been compelling. In the last two years mutations in CHCHD10, which codes for a bona fide mitochondrial protein, have been reported by several groups internationally in patients with ALS, FTD and other motor neuron diseases. The disease is dominantly inherited, as are most familial forms of ALS, but the function of the gene remains completely unknown. This project aims to identify the normal function of CHCHD10 and elucidate the mechanism of the mutant forms of the protein in motor neurons derived from patient cells and in a zebrafish model of the disease.
Montréal - Centre Hospitalier de l'Université de Montréal

Alex Parker Ph.D

RG15  TIR-1/Sarm1 mediated degeneration of motor neurons in ALS

$100,000.00  2/1/2016  1/31/2017  Year 1
$100,000.00  2/1/2017  1/31/2018  Year 2
$100,000.00  2/1/2018  1/31/2019  Year 3

Summary  Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the selective death of motor neurons. Even though recent advances have discovered many of the genetic causes of ALS, it remains an incurable disease. To learn more about disease mechanisms and identify new therapeutic approaches we use the genetic system Caenorhabditis elegans, a nematode worm with powerful and rapid methodologies to model ALS. Using our C. elegans ALS models we discovered that the immune system is inappropriately activated via the protein TIR-1/Sarm1 and contributes to cell death. We propose that inactivating this TIR-1/Sarm1 signalling cascade, either genetically or with drugs will alleviate neuronal degeneration caused by mutant human proteins linked to ALS. We will investigate the TIR-1/Sarm1 pathway as a new therapeutic target for ALS in C. elegans and mouse models.

Christine Vande Velde Ph.D.

RG15  Misfolded SOD1 species and mitochondrial quality control in ALS

$100,000.00  2/1/2016  1/31/2017  Year 1
$100,000.00  2/1/2017  1/31/2018  Year 2
$100,000.00  2/1/2018  1/31/2019  Year 3

Summary  Amyotrophic lateral sclerosis is a progressive and ultimately fatal neurodegenerative disease, characterized by the loss of specialized neurons that control voluntary muscle movement. The loss of these neurons, termed motor neurons, results in progressive weakening and ultimately paralysis of skeletal muscles. Affected individuals gradually lose their ability to move, speak, swallow and eventually breathe. The biological basis of specificity and the mechanism of how motor neurons are lost in ALS remains unknown. The second most common cause of familial inherited ALS and a portion of non-inherited sporadically occurring ALS cases are due to genetic mutations in superoxide dismutase 1. Mutant SOD1 protein adopts a non-normal/ misfolded structure, which leads it to associate with motor neuron mitochondria in an aberrant manner. Mitochondria are the power generators of the cells and neurons highly depend on them. The mechanism is unclear, but the association of non-normal SOD1 with these organelles causes damage. Mitochondria are equipped with a quality control system that normally safeguards against such insults. Thus, it is puzzling why damaged mitochondria increasingly accumulate and harm motor neurons in ALS.

Québec - CHU de Québec

Jack Puymirat M.D., Ph.D.

RG16  Elimination of toxic RNA in myotonic dystrophy brain

$93,215.00  8/1/2016  7/31/2017  Year 1
$96,319.00  8/1/2017  7/31/2018  Year 2
$89,003.00  8/1/2018  7/31/2019  Year 3

Summary  Myotonic Dystrophy type 1 (DM1) is a multisystemic dominant disease caused by a CTG expansion in the DM1 gene. Pathogenic RNAs are retained in nuclear aggregates that sequester nuclear factors, ultimately leading to abnormalities of RNA maturation and clinical symptoms. There is increasing amount of evidence indicates that elimination of toxic RNA to inhibit its toxicity represents a valuable therapeutic strategy for DM1. Currently, there is no curative treatment available for this RNA-dominant disease. We will develop and evaluate antisense oligonucleotide technology including chemically modified antisense oligonucleotides and peptides oligonucleotides to abolish RNA toxicity by degrading CUGexp-RNA. Human DM1 neuronal cells derived from DM1 iPSC and animal models (DMSXL mice) are available. The incapacity of antisense oligonucleotides to effectively cross the blood-brain barrier indicate that other delivery methods will have to be considered for the treatment of DM1 CNS dysfunction and cognitive impairment, which have dramatic repercussion on the quality of life of patients. To this end, intraventricular injection in mice could resolve this issue and will be investigated. In human, intrathecal administration of ASO ISIS-SMRx in patients with infantile spinal muscular atrophy cleared a phase III human study, showing the potential for this approach in DM1.

CHILE
Summary

Amyotrophic lateral sclerosis (ALS) is a progressive and deadly adult-onset motoneuron disease characterized by muscle weakness, atrophy, paralysis and premature death. The primary mechanism responsible for the progressive motoneuron loss in ALS remains unknown. Clues have been obtained from families with sporadic and familial ALS, which are accompanied by alterations in the folding of important proteins including SOD1, TDP43, FUS, among other factors. Perturbations of the protein folding functions performed at a subcellular organelle called the endoplasmic reticulum (ER) have been extensively suggested as a common factor driving motoneuron dysfunction in ALS. ER homeostasis alterations are one of the earliest defects observed in ALS models, which may drive initial disease stages that trigger loss of motor control and later death of motoneurons. We have obtained preliminary data supporting the involvement of a specific ER stress sensor in neuroprotection against experimental ALS. In this project we will develop a systematic approach and define for the first time the relative contribution of this main stress pathway in ALS models. We plan to use genetic and pharmacological approaches to target the ER stress factor in different mouse models of ALS and human ALS neurons, measuring the impact on disease progression, life span, and histopathological features. This work may lead to the design of novel therapeutic strategies to treat this fatal neuromuscular disease.

CYPRUS

Nicosia - The Cyprus Institute of Neurology & Genetics

Kleopas A. Kleopa M.D.

RG16 Expanding the gene therapy approach for treating CMT1X

$57,794.00  2/1/2017  1/31/2018  Year 1

$62,205.00  2/1/2018  1/31/2019  Year 2

Summary

The goal of this project is to advance and expand our gene therapy approach already developed in a previously funded MDA project to treat the X-linked form of Charcot-Marie-Tooth Disease. Using mouse models of this disease we have demonstrated that by a lumbar injection of a viral vector carrying the normal gene that is mutated in patients we can achieve expression of the normal protein in multiple nerves leading to improvement of the peripheral nerve pathology and motor performance in this model. Here we would like to overcome further issues that are important to expand this approach. Since we only used a single injection of the vector so far we will examine whether repeated injections can lead to higher expression rates. In addition, we will test whether treatment at later stages of the neuropathy in the disease model could provide similar benefit as the early treatment we used so far, a very relevant question for treating patients at various stages of the disease. We furthermore need to validate our method in a large animal model to prove that sufficient distribution of the vector can be achieved in a scale relevant for patients. Finally, we will develop a gene repair method for a subset of patients who may harbor mutated proteins that could negatively interact with the normal protein delivered by the vector, as suggested by our recent results. Overall, this project will advance the translation potential of gene therapy for this and other forms of inherited neuropathy.

FRANCE

Nantes - University of Nantes, INSERM UMR 1089

Philippe Moullier MD, PhD

RG16 Gene therapy for the cardiac disease in Duchenne Muscular Dystrophy

$100,000.00  8/1/2017  7/31/2018  Year 1

$100,000.00  8/1/2018  7/31/2019  Year 2

$100,000.00  8/1/2019  7/31/2020  Year 3

Summary

The aim of our program is to deliver preclinical data that will enable translation to the treatment of the cardiac disease in Duchenne patients by gene therapy. We are two teams committed (George Dickson, PhD, University of London, UK and Philippe Moullier, MD, PhD/Caroline Le Guiner, PhD University of Nantes, France) to this 3-year program. What, we believe, makes our program competitive is: (i) our combined expertise in gene therapy for Duchenne disease; (ii) our direct access to critical animal models among which the unique DMDmdx rat exhibiting a similar cardiac phenotype as to the one described in Duchenne
patients; (iii) the direct access to multiple core facilities specialized in translational gene therapy programs. We will address the therapeutic potential of 2 murine mini-dystrophin genes that are expected to behave differently in vivo. They will be compared along side a near normal size dystrophin resulting from correction by exon skipping. We will use the viral vector AAV9 (known for its heart tropism) in three animal models: (i) the mdx mouse to mainly investigate the molecular interactions of the mini-dystrophin candidates with their expected physiological partners; (ii) the DMDmdx rat to mainly assess the functional cardiac stabilization/recovery by EKG and 2D-echocardiography; and (iii) the nonhuman primate to determine the optimal AAV9 dose after selective intracoronary injections and molecular determination of gene transfer efficacy.

ITALY

Rome - Fondazione Telethon

Maria Pennuto Ph.D.

RG16 Targeting activity-regulated (dys)function of androgen receptor in SBMA neurons

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>2/1/2017</td>
<td>1/31/2018</td>
<td>Year 1</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>2/1/2018</td>
<td>1/31/2019</td>
<td>Year 2</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>2/1/2019</td>
<td>1/31/2020</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Summary

A mutation in the androgen receptor (AR) causes selective lower motor neuron degeneration with an unknown mechanism in spinobulbar muscular atrophy (SBMA). We will test the hypothesis that the function of AR is regulated by neuronal activity through direct modification of AR itself, and that this process is altered by the mutation that causes SBMA. This hypothesis is based on our preliminary data, showing that modification of mutant AR by a factor named cyclin-dependent kinase 2 (CDK2) enhances neurotoxicity. To test our hypothesis, we will pursue these goals: To identify AR as a factor whose function is regulated by neuronal activity. We will test the hypothesis that AR activation in neurons is regulated by their activity through direct modification of the disease protein, and that this level of regulation of protein function is altered by the mutation causing SBMA. To assess the role of CDK2-mediated polyQ-AR modification in SBMA. We will test the hypothesis that elimination of CDK2 reduces the toxicity of mutant AR by direct modification of the disease protein. To identify specific inhibitors for therapy development. We will assess the efficacy of specific inhibitors of CDK2 to identify compounds for therapy development.

Trieste - International Centre for Genetic Engineering and Biotechnology

Franco Pagani MD

RG15 Exon Specific U1 snRNAs as a therapeutic approach for spinal muscular atrophy

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$76,450.00</td>
<td>2/1/2016</td>
<td>1/31/2017</td>
<td>Year 1</td>
</tr>
<tr>
<td>$74,800.00</td>
<td>2/1/2017</td>
<td>1/31/2018</td>
<td>Year 2</td>
</tr>
<tr>
<td>$73,700.00</td>
<td>2/1/2018</td>
<td>1/31/2019</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Summary

Spinal muscular atrophy (SMA) is a severe neuromuscular disease with no effective treatment. One of the most promising strategy is to act directly on the SMN2 gene and in particular on its “splicing” at the level of RNA, to force the gene to produce the missing protein. In this proposal, we intend to evaluate a novel therapeutic approach for SMN2 splicing correction based on small RNAs named “Exon Specific U1 snRNA” (ExSpeU1). In this project, we intend to evaluate the therapeutic and safety profile of ExSpeU1s in vivo in different mice SMA models. These studies will contribute to the development of an effective therapeutic approach for the treatment of SMA.

NETHERLANDS

Baarn - European Neuro Muscular Centre

Alexandra Breukel PhD

CG Recommendations for treatment of mitochondrial DNA maintenance disorders

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5,000.00</td>
<td>4/1/2017</td>
<td>6/30/2017</td>
<td>Year 1</td>
</tr>
</tbody>
</table>

Summary

The ENMC has dedicated at least 2 workshops to this group of diseases in the past (September 2007, workshop 155, “Polymerase gamma and disorders of mitochondrial DNA synthesis”, and December 2008, workshop 163, “Mitochondrial DNA disorders”. Many significant advances have been achieved in this field since 2008, including the discovery of new genes involved, and most importantly, significant preclinical and clinical evidence on the plausibility of new therapies, such as the dN-based treatments, or new therapy approaches for mitochondrial neurogastrointestinal encephalopathy (MNGIE) under preclinical development or already applied to patients. Therefore, we think that a workshop fully dedicated to discuss these advances on therapy is critical because it will be extremely valuable for basic and clinical researchers and would impact patients who are candidates for these treatments. The workshop aims to reach a consensus
agreement on evidence-based recommendations for genetic diagnostic and treatment of these diseases. Expected number of attendees is 21.

**Nijmegen - Radboud University Nijmegen Medical Centre (2)**

**Erik Storkebaum Ph.D.**

**RG16**  
Unraveling mechanisms by which mutant tRNA synthetases cause CMT neuropathy  
$99,000.00  
2/1/2017  
1/31/2018  
Year 1  
$94,500.00  
2/1/2018  
1/31/2019  
Year 2  
$97,500.00  
2/1/2019  
1/31/2020  
Year 3

**Summary**  
In Charcot-Marie-Tooth (CMT) disease, the nerve cables which connect the muscles and skin to the spinal cord degenerate. This leads to muscle wasting, impaired movement, and loss of sensation. Mutations in five distinct genes encoding tRNA synthetases all cause CMT. tRNA synthetases play an essential role in the production of proteins. Although some mutations may result in the loss of the normal function of these proteins, it has been shown that at least a number of mutations result in the acquisition of a toxic function that results in the impaired production of new proteins. In this proposal, we wish to determine whether or not all mutant tRNA synthetases cause disease through acquisition of a novel, toxic function. Furthermore, we want to test the hypothesis that all mutant tRNA synthetases cause impaired production of new proteins. These investigations form an essential first step towards the design of effective treatments for these diseases.

**SPAIN**

**Barcelona - Universitat Pompeu Fabra**

**Pura Munoz-Canoves Ph.D.**

**RG16**  
Understanding and reversing muscle stem cell regenerative decline in DMD  
$99,990.00  
8/1/2016  
7/31/2017  
Year 1  
$99,950.00  
8/1/2017  
7/31/2018  
Year 2  
$99,956.00  
8/1/2018  
7/31/2019  
Year 3

**Summary**  
The studies outlined in this proposal aim to answer fundamental questions on the biology of stem cells in skeletal muscle (satellite cells) in Duchenne Muscular Dystrophy (DMD). We want to understand why the capacity of satellite cells declines over the course of DMD progression, since this will help to envision new pathways to enhance or restore muscle regeneration in these patients, particularly at advanced age, when muscle architecture is disrupted, and loss of regenerative capacity is maximal. We would like to prove that the loss of regenerative capacity of satellite cells in dystrophic muscle is an autophagy-dependent process and that promoting autophagy in these cells - via administration of natural compounds - can restore their regenerative properties even at advanced DMD stages. - Presently, there are no Agencies or Patients' Associations in Spain to submit nor fund this proposal. - Presently, there are no Agencies or Patients' Associations in Spain to submit nor fund this proposal.

**Madrid - Centro de Investigaciones Biologicas-CSIC**

**Natalia Rodriguez Muela Ph.D.**

**DG15**  
Autophagy controls SMN protein degradation  
$59,995.00  
2/1/2016  
1/31/2017  
Year 1  
$59,995.00  
2/1/2017  
1/31/2018  
Year 2  
$59,995.00  
2/1/2018  
1/31/2019  
Year 3

**Summary**  
Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of infant mortality. SMA is caused by mutations or the complete deletion of the SMN gene that lead to the deficiency of the survival motor neuron (SMN) protein. It is unanimously accepted that increasing SMN levels restores the diseased phenotype and will be therapeutically valuable for treating patients with SMA. Accumulating evidence suggests that the ubiquitin/proteasome system regulates SMN protein levels. However, whether the other major catabolic mechanism within the cell, the lysosomal/autophagy pathway, is also involved in SMN degradation is completely unexplored. Autophagy is a highly conserved intracellular degradative pathway that plays a critical role in the removal of cell components to maintain cellular homeostasis and has been implicated in the pathology of many neuromuscular disorders. Whereas the proteasome is in charge of degrading short-lived single proteins, autophagy engulfs protein aggregates, protein complexes and cellular organelles and it can do so in a bulk or selective way. Multiple links demonstrating cross-talk between these degradative systems have been reported. The overall goal of this study is to explore the role
that autophagy plays in controlling SMN protein levels. Specifically blocking autophagy-dependent SMN degradation may constitute a new approach to find new targets for SMA therapeutic intervention.

UNITED KINGDOM

Edinburgh - University of Edinburgh

Lyndsay Murray Ph.D

RG16 Understanding and Exploiting the Therapeutic Time Window in Mouse Models of SMA

$94,268.00  8/1/2016  7/31/2017  Year 1

$98,611.00  8/1/2017  7/31/2018  Year 2

$99,295.00  8/1/2018  7/31/2019  Year 3

Summary

SMA is a devastating motor neuron disease affecting primarily children, which is the result of degeneration of the cells known as motor neurons. This disease is caused by defects in a gene known as ‘survival motor neuron 1’, or SMN1. A number of therapeutic options have been proposed for SMA. Among the most promising of these, are strategies that are based on restoring the levels of SMN. Importantly, animal model trials revealed that while administration of the therapeutic can nearly rescue an individual from the disease when given before symptoms start, but the benefits are vastly reduced when therapies are given later, even at very early stages of the disease. As we will likely be treating patients after symptom onset, it is very important to understand why the benefits of therapeutics are so limited after symptoms have started, and find way in which to maximize the benefits during symptomatic stages of the disease. We aim to understand how long it takes for motor neurons to recover following restoration of SMN function and to understand how this process differs when the Smn gene is repaired at symptomatic stages of disease. We also plan to give other drugs, at the same time as repairing the SMN gene to see if they can add additional benefit when the gene is fixed at symptomatic stages of disease. This work will help us understand what limits the benefits of the therapeutics currently under development, and will investigate ways in which to make them work better.

Liverpool - University of Liverpool

Addolorata Pisconti PhD

RG Role of serine protease activity in the pathogenesis of muscular dystrophy

$100,000.00  8/1/2016  7/31/2017  Year 2

$100,000.00  8/1/2017  7/31/2018  Year 3

Summary

Receiving a diagnosis of Duchenne muscular dystrophy (DMD) is devastating because there is currently no cure; moreover important aspects of what causes muscle loss in DMD remain to be understood. For example, it is not clear why the muscles of DMD children soon stop to regenerate themselves. We believe that this happens in part because cells that would normally regenerate the muscle when it is injured (called satellite cells) are exposed to a hostile environment generated by the continuous tissue damage caused by dystrophin loss. We have discovered that the levels of a family of proteins called serine protease inhibitors, which participate in the regulation of the response to tissue injury, are dramatically altered in the muscle of dystrophic mice. Furthermore, we found that addition of serine protease inhibitors to satellite cell cultures affects several satellite cell functions that are essential to ensure successful muscle regeneration. Thus, we propose to investigate whether the changes observed in mice also occur in children with DMD and to study the mechanisms through which serine protease activity regulates satellite cell regenerative capacity. This work is important because drugs targeting serine protease activity already exist and might be rapidly available in patients if proven to be useful in DMD models. Moreover, improving muscle regeneration will also improve the chance of success of gene therapies that are currently under development.

London - Institute of Neurology, University College London

Henry Houlden M.D., Ph.D., MRCP

RG15 Understanding early-onset neuropathies using genome and transcriptome sequencing

$98,357.00  2/1/2016  1/31/2017  Year 1

$99,212.00  2/1/2017  1/31/2018  Year 2

$90,582.00  2/1/2018  1/31/2019  Year 3

Summary

Identifying the causative gene and understanding the mechanism is essential in developing effective disease therapies. Severe early-onset neuropathies are a diverse group where many patients remain undiagnosed and there are few treatments. We have worked extensively on a group of early-onset inherited neuropathies that range from severe early-onset pure neuropathy through to extreme phenotypes characterized by progressive bulbar palsy, respiratory problems and neuropathy that in the past were called Brown-Vialetto-Van Laere (BVVL) or Fazio-Londe syndrome after the describing physicians. In around 35%
of BVVL and Fazio-Londe patients mutations in two riboflavin transporter genes have been identified where high-dose riboflavin supplements are an effective treatment, in some instances life-saving. We have built up a large series of genetically undefined inherited neuropathy patients. From this group we selected 30 genetically negative severe probands with additional DNA collected from parents and siblings as a trio/small family, with either white blood or skin cells, or muscle available for RNA/protein studies. In this proposal we plan to identify and characterize the disease genes in this group using whole genome sequencing to identify the disease associated variants, then use RNA sequencing to narrow down the mutation by identifying aberrant RNA splicing or reduced RNA expression (lost function) and subsequently characterize the disease genes in mammalian and patient cells.

**London - University College London**

**Federica Montanaro Ph.D.**

**Defining the role of impaired Hedgehog signaling in DMD**

<table>
<thead>
<tr>
<th>RG</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>$84,600.00</td>
<td>In Duchenne muscular dystrophy (DMD), fibrosis and progressive failure of muscle regeneration are two major contributors to loss of motor function, progression of cardiac disease, and subsequent mortality. Therefore, intense research efforts are aimed at defining pathways that regulate fibrosis and regeneration in DMD, with the prospect of using this information to develop novel treatment approaches. Our laboratory has discovered for the first time that a signaling pathway called Hedgehog shows decreased activity in muscle biopsies from DMD patients, and in skeletal and cardiac muscle of mdx mice, a model of DMD. We further find that active Hedgehog signaling inhibits fibrosis while promoting muscle regeneration by activating muscle stem cells. Therefore, the goal of this study is to understand the consequences of decreased Hedgehog signaling for skeletal and cardiac muscle disease progression in DMD. In this project we will 1) study how decreased Hedgehog signaling affects muscle stem cells during muscle repair, and 2) test whether increasing Hedgehog signaling in the mdx mouse prevents loss of muscle tissue and preserves muscle function.</td>
</tr>
</tbody>
</table>

**Oswestry - Robert Jones & Agnes Hunt Hospital**

**Glenn Eric Morris D. Phil.**

**The MDA Monoclonal Antibody Resource for Neuromuscular Disease**

<table>
<thead>
<tr>
<th>RG</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>$51,424.00</td>
<td>The MDA Monoclonal Antibody Resource was funded by MDA until Oct 31st, 2013 and by that date nearly all of the most popular hybridomas had been transferred to the Iowa Hybridoma Bank (DSHB) and are also available from that source. We have continued to respond to antibody requests and to maintain the website for nearly two years since MDA funding ceased. We are now applying for further funding for 2-years (part-time) in order to achieve additional specific aims, including making available new antibodies developed recently. The antibodies (over 300) are widely used in clinical trials of Duchenne MD therapy, in therapy trials on animals and in basic research to find novel therapies.</td>
</tr>
<tr>
<td>$46,546.00</td>
<td>The MDA Monoclonal Antibody Resource for Neuromuscular Disease</td>
</tr>
</tbody>
</table>

**UNITED STATES**

**ALABAMA**

**Birmingham - The University of Alabama at Birmingham**

**Michael Miller Ph.D.**

**Postnatal Origin of Amyotrophic Lateral Sclerosis**

<table>
<thead>
<tr>
<th>RG15</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron degeneration. The average age of symptoms is in the mid-fifty’s. Despite great efforts, nearly all tested ALS therapies have failed to provide benefits in clinical trials. The major limitation in developing effective therapeutics for ALS is inadequate understanding of the causal mechanisms. We have been studying the Vapb/ALS8 protein because Vapb loss causes ALS. Investigating the “normal” Vapb function is providing valuable clues to ALS pathogenesis. Our studies in worms, flies, mice, and humans support the model that Vapb is a circulating factor important for skeletal muscle energy metabolism. Preliminary data in this proposal suggest that Vapb is critical during postnatal reproductive development (i.e. circa puberty) and early adulthood. These data have important implications for ALS therapies, which could fail because disease onset occurs much earlier than clinical detection. Indeed, we have identified compensatory mechanisms</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>$100,000.00</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>$100,000.00</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>$100,000.00</td>
</tr>
</tbody>
</table>

**UNITED STATES**

**ALABAMA**

**Birmingham - The University of Alabama at Birmingham**

**Michael Miller Ph.D.**

**Postnatal Origin of Amyotrophic Lateral Sclerosis**

<table>
<thead>
<tr>
<th>RG15</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron degeneration. The average age of symptoms is in the mid-fifty’s. Despite great efforts, nearly all tested ALS therapies have failed to provide benefits in clinical trials. The major limitation in developing effective therapeutics for ALS is inadequate understanding of the causal mechanisms. We have been studying the Vapb/ALS8 protein because Vapb loss causes ALS. Investigating the “normal” Vapb function is providing valuable clues to ALS pathogenesis. Our studies in worms, flies, mice, and humans support the model that Vapb is a circulating factor important for skeletal muscle energy metabolism. Preliminary data in this proposal suggest that Vapb is critical during postnatal reproductive development (i.e. circa puberty) and early adulthood. These data have important implications for ALS therapies, which could fail because disease onset occurs much earlier than clinical detection. Indeed, we have identified compensatory mechanisms</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>$100,000.00</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>$100,000.00</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>$100,000.00</td>
</tr>
</tbody>
</table>
that protect against muscle energy deprivation during aging. Here we will use worms and mice to further investigate Vapb and identify early biomarkers. Early detection is the key to eliminating disease. As Vapb is a circulating hormone like insulin, Vapb injections could be therapeutic.

Marek Napierala Ph.D.

RG16  Oligonucleotide-mediated therapy of Friedreich’s ataxia
$92,907.00  8/1/2016  7/31/2017  Year 1
$94,107.00  8/1/2017  7/31/2018  Year 2
$92,504.00  8/1/2018  7/31/2019  Year 3

Summary  Friedreich’s ataxia (FRDA), a severe progressive neurodegenerative disorder, is caused by an increasing number of specific DNA sequences, termed GAA repeats, that are present in the Friedreich’s ataxia gene (FXN). This error in DNA causes a block in the flow of the information from DNA to RNA, and ultimately leads to a deficiency of the final FXN product, a protein called frataxin. All FRDA patients produce a small amount of frataxin that functions, yet this amount is insufficient to maintain healthy cells. In the proposed project we will take a novel approach aimed to increase the amount of frataxin in patient cells. We will use molecules called oligonucleotides, small specific DNA fragments that can spontaneously enter diseased cells, locate frataxin RNA, and stabilize this important intermediate to increase its “molecular lifespan” in patient cells. This strategy does not increase production of the frataxin RNA, which has proven to be difficult, but instead allows existing frataxin RNA to be available longer for the process of frataxin protein production. We predict that the result of oligonucleotide treatment will be an increased amount of frataxin protein in FRDA patient cells. In summary, this work is contributing to the development of novel strategy to treat frataxin deficiency in Friedreich’s ataxia.

ARIZONA

Oro Valley - ICAGEN-T

Paul August Ph.D.

RG15  ALS Patient Derived Neuron-Muscle Contraction Unit on a Chip
$99,500.00  2/1/2016  1/31/2017  Year 1
$99,500.00  2/1/2017  1/31/2018  Year 2
$99,500.00  2/1/2018  1/31/2019  Year 3

Summary  Neurons are a major part of the electrical system in the human body and skeletal muscles are the main contraction units that are activated by neuronal stimulation. In order to fully model how neuronal function is altered in disease states, the neurons need to be connected to muscles that respond to their stimulation. Historically, animal models have not represented neuromuscular diseases very well which has created difficulties for advancing new therapies. We propose to create a human motor neuron and skeletal muscle contraction unit in the laboratory to more appropriately model human neuromuscular disease, the neuromuscular junction and to permit the rapid evaluation of therapeutic pharmacological agents in the laboratory. This system would be designed entirely using human derived cells from patients with ALS disease.

Phoenix - Dignity Health dba St. Joseph’s Hospital & Medical Center

Rita Sattler

RG  Role of synaptic dysfunction in C9orf72-mediated pathogenesis
$100,000.00  8/1/2016  7/31/2017  Year 2
$100,000.00  8/1/2017  7/31/2018  Year 3

Summary  The goal of this proposal is to study cellular and molecular mechanisms of disease pathogenesis induced by the novel C9orf72 mutation found to be highly prevalent in ALS patients. In specific, we will test the hypothesis that mutant C9orf72 leads to significant changes in the cellular structure of fine projections of neurons, so called axons and dendrites, which are important for the transmission of information from one cell to another. Preliminary data suggest that there is a dysfunction of the dendritic synapse, a specialized structure along those neuronal processes where signal transmission occurs, but also where memories are formed and lost, as is the case during cognitive impairment, as frequently observed in C9orf72 ALS patients. Using C9orf72 ALS patient-derived adult induced pluripotent stem (iPS) cells we will study the mechanisms that alter synaptic proteins in regards to expression, localization and subsequently synaptic function. All human iPS cell culture in vitro studies will be followed up and validated with in vivo analyses of newly developed C9orf72 mouse models. The identification of these novel disease pathways is crucial for understanding C9orf72 disease pathogenesis and for the development of future therapeutics for disorders characterized by the C9orf72 mutation.
Scottsdale - Iron Horse Diagnostics, Inc.

Andreas Jeromin Ph.D.

MVPNEW Validation of biomarkers to support ALS drug development

$55,000.00 4/3/2017 4/3/2017 Year 1
$71,500.00 4/14/2017 10/18/2017 Year 2
$90,200.00 10/19/2017 12/3/2017 Year 3
$16,500.00 12/4/2017 5/3/2018 Year 4

Summary

Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease) is a progressive and fatal neuromuscular disease marked by limb weakness, swallowing and breathing problems, and muscle atrophy. The average time to diagnose ALS is approximately 13 months. Iron Horse Diagnostic is preparing to launch the first biologic ALS diagnostic test. A simple and inexpensive test that will yield results within days, not months, allowing for quicker therapeutic intervention for the patient. During research for our diagnostic test, Iron Horse began developing indicators (biomarkers) of ALS disease progression. These prognostic tests can be used to support therapeutic clinical trials and speed the development of life saving drugs for ALS. Iron Horse is requesting funding to finalize development of our prognostic biomarkers and to launch the tests to the market. These tests will be essential tools to enhance drug development efforts in ALS.

Tucson - Arizona Board of Regents, University of Arizona

Daniela Zarnescu Ph.D.

RG16 Metabolic dysregulation in ALS

$99,951.00 8/1/2016 7/31/2017 Year 1
$99,881.00 8/1/2017 7/31/2018 Year 2
$99,986.00 8/1/2018 7/31/2019 Year 3

Summary

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurological disorder characterized by motor neuron loss and muscle atrophy. With the recent identification of cellular aggregates containing TDP-43 and the discovery of TDP-43 mutations in patients, this protein has emerged as a common denominator for the majority of ALS cases. We have developed a fruit fly model of ALS based on TDP-43, which exhibits alterations in locomotor function and lifespan that are remarkably similar to the human disease. Using this model we have identified specific alterations in the cellular metabolic pathways that govern energy production in motor neurons affected by ALS. These findings suggest increased glucose utilization and defects in the way mitochondria, the cell’s power plants are utilizing fatty acids for energy production. Preliminary studies in the fly model show that locomotor defects are rescued by improving glucose or lipid metabolism in motor neurons via genetic manipulation or specific dietary changes. Given the presence of comparable alterations between fly models and ALS patients we propose to use molecular and genetic tools together with dietary intervention to restore cellular energetics. Our studies in the fly will be validated in patient derived motor neurons, which will help establish the feasibility of developing therapeutic strategies aimed at restoring defects in energy production in affected motor neurons and glia.

CALIFORNIA

Davis - The Regents of the University of California (University of California Davis)

Gino Cortopassi Ph.D.

RG16 A drug for mitochondrial biogenesis in humans for muscle disease

$100,000.00 8/1/2017 7/31/2018 Year 1
$100,000.00 8/1/2018 7/31/2019 Year 2
$100,000.00 8/1/2019 7/31/2020 Year 3

Summary

A critical step for the approval of drug therapy for muscle disease is FDA approval. There are currently no FDA-approved drugs for mitochondrial muscle diseases (myopathies) in the USA. We show that the drug DMF increases the number and function of mitochondria in mice and humans. This drug DMF is the ONLY FDA-approved drug in the USA and Europe that has been shown to increase mitochondria, it is unique. We propose to test it in an animal model of mitochondrial muscle disease, and of Duchenne’s muscular Dystrophy. If the drug is effective these are crucial data to enable the FDA allowing us to try DMF for the treatment of Mitochondrial Myopathy, or of Duchenne’s Muscular Dystrophy. Because DMF is Already Approved for use in humans, this is a much shorter path to the clinic than starting with a completely new drug molecule, and gets drug to patients who need it faster.

Ricardo Anibal Maselli M.D.
**RG**  
Replacement Therapy for Congenital Deficiency of Endplate Acetylcholinesterase  
$100,000.00  
8/1/2016  
7/31/2017  
Year 2  
$100,000.00  
8/1/2017  
7/31/2018  
Year 3

**Summary**  
Congenital endplate acetylcholinesterase (AChE) deficiency is a human disease characterized by fatigable muscle weakness that results from an abnormal transmission of electrical signals through the neuromuscular junction (NMJ). Congenital endplate AChE deficiency is caused by a genetic deficiency of the collagen Q (ColQ), which is the protein that anchors AChE to the NMJ. There is currently no effective treatment for human deficiency of endplate AChE. The main goal of this project is to test the therapeutic effect of introducing genetically modified mesenchymal stem cells (MSCs) expressing high levels of ColQ into engineered mice that lack ColQ and have severe muscle weakness. The ultimate goal of the project is to implement therapies for human deficiency of endplate AChE based on the replacement of ColQ at the NMJ.

**La Jolla - Ludwig Institute for Cancer Research Ltd**  
**Don Cleveland Ph.D.**

**RG**  
Mechanisms underlying neurotoxicity caused by ALS-linked mutations in FUS/TLS  
$100,000.00  
8/1/2016  
7/31/2017  
Year 2  
$100,000.00  
8/1/2017  
7/31/2018  
Year 3

**Summary**  
Amyotrophic lateral sclerosis (ALS) is a progressive, fatal adult-onset neurodegenerative disorder, characterized by the selective loss of motor neurons. Recent breakthrough discoveries of mutations in the transactive response RNA-binding protein (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS/TLS) as causative of ALS and Frontotemporal dementia (FTD), combined with the abnormal aggregation of these RNA binding proteins, suggest that perturbations in both RNA and protein homeostasis may contribute to neurodegeneration. Unresolved is whether pathogenesis in TDP-43- or FUS/TLS-mediated disease results from a gain of toxic property(ies) associated (or not) with their cytoplasmic inclusions and/or a loss of nuclear function of either protein. To evaluate the contribution of gain of toxic property(ies) of FUS/TLS and the role of its aggregation in ALS/FTD, disease-specific changes in FUS/TLS protein interaction will be identified using new FUS/TLS-mediated ALS mouse models which develop adult-onset progressive neurodegeneration. The toxic potency of the aggregation-prone capacity of FUS/TLS will be tested using synthetic FUS/TLS fibrils in both cellular and mouse models. This multi-pronged approach is designed to resolve the nature of FUS/TLS interacting partners that are altered in disease as well as the contribution of FUS/TLS aggregation to pathogenesis, thus providing potential directions for therapies.

**Jie Jiang Ph.D.**

**DG16**  
Role of C9orf72 loss of function in ALS caused by GGGGCC repeat expansions  
$60,000.00  
2/1/2017  
1/31/2018  
Year 1  
$60,000.00  
2/1/2018  
1/31/2019  
Year 2  
$60,000.00  
2/1/2019  
1/31/2020  
Year 3

**Summary**  
Amyotrophic lateral sclerosis (ALS) is a progressive, fatal adult-onset neurodegenerative disorder, characterized by the selective loss of motor neurons leading to paralysis. Expanded GGGGCC hexanucleotide repeats in a non-coding region of the C9orf72 gene are the most common genetic cause of ALS and frontotemporal dementia (FTD), another neurological disease characterized by behavioral and language changes. Proposed pathogenic mechanisms include reduction in endogenous C9orf72 protein function and/or a toxic gain of function from the repeat-containing RNAs mediated either by sequestration of RNA binding proteins or by translation of those RNAs into aberrant dipeptide repeat proteins. My previous efforts have established that C9orf72 repeat expansions contribute to ALS/FTD disease pathogenesis in part by a gain of toxicity mechanism and that reduced expression of C9orf72 in mice alone is insufficient to produce ALS/FTD. Additional efforts have suggested that loss of C9orf72 alters function of microglia, the immune cells in the central nervous system, and that this may be a contributor to neurodegeneration in C9orf72 expansion carriers. This proposal will use genetics in mice to determine whether C9orf72 loss of function synergizes with gain of toxicity to produce, to understand the role C9orf72 in microglia, and establish its contributions to ALS/FTD. The outcome of this proposal will guide direction of therapeutic development for ALS/FTD caused by C9orf72 repeat expansions.

**La Jolla - Sanford Burnham Prebys Medical Discovery Institute**  
**Pier Lorenzo Puri M.D.**

**RG16**  
Role of fibroadipogenic progenitor subpopulations in Duchenne Muscular Dystrophy  
$99,655.00  
8/1/2016  
7/31/2017  
Year 1
Duchenne Muscular Dystrophy (DMD) is the most common form of muscular dystrophy, for which there is no available cure. Pharmacological control of disease progression is a suitable strategy to slow down the functional decline of dystrophic muscles. Targeting key pathogenic events of disease progression, such as transition from compensatory regeneration to fibrotic and fatty infiltration, is currently the focus of therapeutic interventions. This proposal will investigate the functional interplay between key cellular determinants (including muscle stem cells and component of their “niche”) of skeletal muscle ability to regenerate upon acute injury or undergo fibrosis and fat deposition during chronic diseases, such as DMD. We have established a technological platform and experimental setting that allow to identify and functionally characterize discrete subpopulations of fibro-adipogenic progenitors (FAPs) in mouse models of acute regeneration, DMD progression and macrophage depletion, and will exploit HDAC inhibitors (a treatment currently in clinical trial with DMD boys) to determine the impact of pharmacological interventions on the relative amounts and biological activity of FAP subpopulations.

Alessandra Sacco Ph.D.

RG15 Role of STAT3 signaling in Duchenne Muscular Dystrophy

Summary In Duchenne muscular dystrophy (DMD) the diseased microenvironment plays a deleterious role on muscle stem cell (MuSC) function, thus impairing tissue repair. The goal of these studies is to develop pharmacological approaches to target these negative interactions. We hypothesize that by modulating the sensitivity of MuSC to the diseased microenvironment, we can promote their effective expansion in dystrophic muscle, thus restoring their ability to repair the damaged tissue and delaying disease progression. This proposal builds on our recent proof of principle study showing that transient inhibition of STAT3 signaling promoted MuSC expansion and improved tissue repair in dystrophic mice. In an effort to move this study forward, we will test STAT3 inhibitors (STAT3i) that have already been extensively characterized in preclinical studies, thus accelerating translation to the clinic. We will test the hypothesis that the STAT3 pathway is a major mediator of the deleterious effects of the dystrophic microenvironment on MuSC function. We will assess the effects of STAT3i on these cell-cell interactions and disease progression. For these studies we will utilize the mdx/mTR mouse, a model of DMD we recently developed that closely recapitulates the human DMD disease. These studies would improve our understanding of the progressive decline in tissue maintenance in DMD and develop strategies to ameliorate the disease phenotype that would find applications for regenerative medicine.

La Jolla - The Regents of the University of California, San Diego

Jordan Blondelle PhD

DG16 Role of Cullin-3 targeted protein turnover in skeletal muscles

Summary Protein degradation is an essential mechanism by which a plethora of cellular processes is regulated. The Cullin family of ubiquitin E3-ligases is a key component of that system. Once incorporated into complexes, Cullins are able to bind and mark unwanted proteins for degradation. Recently, mutations in several binding partners of Cullin-3, a Cullin protein family member, were found in patients with severe forms of nemaline myopathy. These findings suggest a specific and important function for Cullin-3 targeted protein degradation during muscle development and in muscle physiology. While intensively investigated in the context of cancer, very few data are available regarding the role of Cullin-3 in muscles. Using mutant mice depleted of Cullin-3 in muscles, we unraveled its absolute necessity for postnatal survival. In this project, we will ask how the loss of Cullin-3 is affecting muscle development, structure and function. We expect to find new target proteins of the Cullin-3 complex that would be misregulated in absence of Cullin-3 and responsible for the deleterious phenotype observed in mice. Indeed, the overall aims of our project are to decipher, for the first time, how protein degradation mediated by Cullin-3 is relevant for muscle physiology and to give us insights regarding the pathological mechanisms leading to nemaline myopathy in patients.

Albert La Spada M.D., Ph.D.

RG16 SBMA motor neuron degeneration: From cellular and molecular basis to therapy

Summary Protein degradation is an essential mechanism by which a plethora of cellular processes is regulated. The Cullin family of ubiquitin E3-ligases is a key component of that system. Once incorporated into complexes, Cullins are able to bind and mark unwanted proteins for degradation. Recently, mutations in several binding partners of Cullin-3, a Cullin protein family member, were found in patients with severe forms of nemaline myopathy. These findings suggest a specific and important function for Cullin-3 targeted protein degradation during muscle development and in muscle physiology. While intensively investigated in the context of cancer, very few data are available regarding the role of Cullin-3 in muscles. Using mutant mice depleted of Cullin-3 in muscles, we unraveled its absolute necessity for postnatal survival. In this project, we will ask how the loss of Cullin-3 is affecting muscle development, structure and function. We expect to find new target proteins of the Cullin-3 complex that would be misregulated in absence of Cullin-3 and responsible for the deleterious phenotype observed in mice. Indeed, the overall aims of our project are to decipher, for the first time, how protein degradation mediated by Cullin-3 is relevant for muscle physiology and to give us insights regarding the pathological mechanisms leading to nemaline myopathy in patients.
$100,000.00  2/1/2018  1/31/2019  Year 2
$100,000.00  2/1/2019  1/31/2020  Year 3

Summary  X-linked spinal & bulbar muscular atrophy (SBMA) is an inherited neuromuscular disorder characterized by lower (spinal cord) motor neuron degeneration. SBMA is caused by CAG/polyglutamine repeat expansions in the androgen receptor gene. My research has focused on defining the cellular and molecular basis of SBMA by using a variety of approaches, including neurons grown in culture, genetically engineered mice, and "stem cell" models derived from SBMA patient skin cells by reprogramming these skin cells to become pluripotent stem cells which we then differentiate into immature neurons, motor neurons, and skeletal muscle. Our published work over the last two years has yielded two important findings for SBMA disease research, with implications for understanding more common motor neuron diseases, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We discovered that expression of mutant AR protein in skeletal muscle is required for SBMA motor neuron disease, and now wish to understand how skeletal muscle dysfunction sickens motor neurons. What we learn may provide targets for therapy development for not only SBMA, but also SMA and ALS. We identified dysfunction of a factor known as TFEB as the cause of SBMA defects in protein quality control pathways, and now propose to determine why this occurs, again expecting that an understanding of this disease mechanism will reveal targets for therapy development for SBMA and related motor neuron diseases.

La Jolla - The Salk Institute for Biological Studies
Pradeep Reddy Dubbaka Venu Ph.D.
DG15  Preventing transmission of mitochondrial myopathies through heteroplasmic shift
$60,000.00  2/1/2016  1/31/2017  Year 1
$60,000.00  2/1/2017  1/31/2018  Year 2
$60,000.00  2/1/2018  1/31/2019  Year 3

Summary  Mitochondrial myopathies are a group of devastating diseases caused by mutations in mitochondrial DNA (mtDNA). Currently genetic counseling and preimplantation genetic diagnosis (PGD) are the best options to prevent the transmission of mitochondrial diseases. In this project we aim to prevent the transmission of mitochondrial myopathies by the selective elimination of mutated mtDNA present in the oocytes. The technique is based on the introduction of nucleases (molecular scissors) into oocytes that enter into mitochondria and specifically identify and eliminate the mutated mtDNA. The feasibility of this approach was recently demonstrated by using nucleases in the mouse embryos where the transmission of targeted mtDNA to next generation was successfully prevented. A similar strategy will be undertaken in human oocytes from mitochondrial disease patients to selectively target and eliminate the mutated mtDNA. The assessment of safety and efficacy of this approach will be beneficial in moving this technology to the clinic in the near future. The results arising from this proposal may potentially lead to the eradication of mitochondrial myopathies.

La Jolla - The Scripps Research Institute
Matthew Disney Ph.D.
RG15  Designer Small Molecules to Manipulate Disease-Causing RNA Repeats
$100,000.00  2/1/2016  1/31/2017  Year 1
$100,000.00  2/1/2017  1/31/2018  Year 2
$100,000.00  2/1/2018  1/31/2019  Year 3

Summary  Myotonic dystrophy type 1 (DM1) is a genetic disease characterized by multisystemic wasting of muscle function, including organ wasting that leads to cardiac disease, respiratory impairment, cataracts, and a host of other significant problems. Likewise, amyotrophic lateral sclerosis (ALS) is a progressive, degenerative disorder of motor neurons, resulting in muscle atrophy and paralysis. Up to 50% of ALS patients also develop abnormalities in behavior, language and personality. Both diseases are caused by a toxic biomolecule. No effective treatment is available for ALS or DM1. Our proposed work focuses on the optimization of two drug-like compounds, one that ameliorates DM1-associated defects in patient-derived cell lines and a mouse model and another that improves ALS-associated defects in patient-derived iNeurons and is blood-brain barrier penetrant. We will engender our compounds with the ability to remove the toxic biomolecule from disease-affected cells. We will also study the selectivity of our compounds in patient-derived cells and mouse models using novel and innovative methods developed by our laboratory. These studies can identify potentially silent off-targets, which could cause side effects. Since any therapeutic for DM1 or ALS would, in principle, be given to a patient for the course of their life, these studies and tools to investigate off-targets are critically important. Collectively, our studies will accelerate treatments for DM1 and ALS patients.
**Los Angeles - Cedars-Sinai Medical Center**

**Robert Baloh M.D., Ph.D.**

**RG**

MFN1 augmentation to suppress toxicity in a novel mouse model of CMT2A

$100,000.00  
8/1/2016  
7/31/2017  
Year 2

$100,000.00  
8/1/2017  
7/31/2018  
Year 3

**Summary**

Charcot-Marie-Tooth (CMT) disease is split into two forms, demyelinating (CMT type 1) and axonal (CMT type 2). Mutations in MFN2 are the most commonly identified cause of CMT type 2, but the mechanism of how altered function of this mitochondrial protein causes nerve damage remains unknown, and no effective animal models exist for the disease. Our lab found that in an in vitro model of the disease, overexpression of MFN1 was able to correct the mitochondrial defects and suppress axon degeneration. We developed a new transgenic mouse model of CMT2A, as well as a new transgenic mouse which overexpresses MFN1. Our goals in this proposal are to (i) characterize the new MFN2 mutant model, and (ii) determine whether increasing MFN1 levels in an animal model can suppress behavioral and pathologic features of the disease. This will provide proof of concept that increasing MFN1 levels is a viable therapeutic strategy in CMT2A.

**Los Angeles - The Regents of the University of California, Los Angeles**

**Steve Cannon MD, PhD**

**RG15**

A mouse model for exercise-induced weakness in hypokalemic periodic paralysis

$100,000.00  
2/1/2016  
1/31/2017  
Year 1

$100,000.00  
2/1/2017  
1/31/2018  
Year 2

$100,000.00  
2/1/2018  
1/31/2019  
Year 3

**Summary**

Hypokalemic periodic paralysis (HypoKPP) is a rare inherited disorder of skeletal muscle in which affected individuals have transient episodes of weakness, lasting hours to days. The attacks of weakness are usually provoked by stress, carbohydrate-rich meals, shifts in blood potassium levels, or follow a period of strenuous physical exertion. The cause for exercise-induced attacks is unknown and therefore therapeutic options are severely limited. Several gene defects have been identified in periodic paralysis, and with prior support from the MDA, we have created genetically modified mice with point mutations in sodium or calcium channel genes and that recapitulate the susceptibility to weakness when challenged with carbohydrate or shifts in potassium. New preliminary studies have revealed a profound loss of force within minutes of recovery from exposure to high carbon dioxide levels. We propose this maneuver is a surrogate for the exercise-induced attacks of weakness that occurs in patients. The discovery of this robust assay in the mouse model provides a unique opportunity in which we will investigate the mechanistic basis for exercise-induced weakness in periodic paralysis, will strategically select drugs that may block this process, and will test the potential of these drugs to foreshorten or prevent attacks of periodic paralysis.

**Rachelle H. Crosbie-Watson Ph.D.**

**RG16**

Improving cell adhesion to protect the dystrophic cardiac sarcolemma

$100,000.00  
8/1/2016  
7/31/2017  
Year 1

$100,000.00  
8/1/2017  
7/31/2018  
Year 2

$100,000.00  
8/1/2018  
7/31/2019  
Year 3

**Summary**

Our proposal will determine whether application of sarcospan treatment for Duchenne Muscular Dystrophies will affect cardiomyopathy disease progression in relevant murine models. We will investigate molecular mechanisms of cardiomyopathy in regulating adhesion and determine whether sarcospan is cardioprotective.

**Melissa Spencer Ph.D.**

**RG15**

Therapeutic Development of Osteopontin Inhibitors as Anti-Fibrotics for Duchenne

$173,663.00  
2/1/2016  
1/31/2017  
Year 1

$143,663.00  
2/1/2017  
1/31/2018  
Year 2

$133,663.00  
2/1/2018  
1/31/2019  
Year 3

**Summary**

The studies are designed to support the development of osteopontin inhibitors to treat Duchenne muscular dystrophy.

**Los Angeles - USC/University of Southern California**

**Justin Ichida Ph.D.**
**Summary**

A massive expansion of a repetitive DNA sequence in a gene called C9ORF72 is the most common cause of ALS. Determining the mechanism of C9ORF72 pathogenesis is crucial for developing effective therapeutics. Recent studies have proposed different mechanisms to explain the motor neuron degeneration resulting from the C9ORF72 repeat expansion, mostly focusing on a gain of toxicity from the expanded C9ORF72 RNA itself or repetitive proteins generated from it. However, the mechanism of neurodegeneration remains unclear. To investigate the role of C9ORF72 protein in ALS pathogenesis, we used "cellular reprogramming" to generate motor nerve cells in the petri dish from the blood of C9ORF72 ALS patients. Using this approach, we have determined that an understudied mechanism, the loss of C9ORF72 protein function, plays a major role in inducing C9ORF72 ALS motor neuron degeneration. We find C9ORF72 ALS motor nerve cells express reduced levels of C9ORF72 protein and that restoring normal expression rescues their survival. In this project, we will use our human motor neuron model and biochemical and genetic methods to 1) Definitively show that the loss of C9ORF72 protein function plays a key role in C9ORF72 ALS, 2) Identify the properties of C9ORF72 that are critical to its protective function in ALS motor neurons and 3) Determine if C9ORF72 is a Rab guanine exchange factor. This work will establish C9ORF72 protein as a key therapeutic target.

**Kim Staats Ph.D.**

**DG15**

The Role of SEC14L5 in ALS

|$60,000.00| 2/1/2016 | 1/31/2017 | Year 1
|$60,000.00| 2/1/2017 | 1/31/2018 | Year 2
|$60,000.00| 2/1/2018 | 1/31/2019 | Year 3

**Summary**

ALS is a relentlessly fatal disease driven by motor neuron cell death. Understanding the effect of mutations in ALS is necessary for development of therapeutic strategies. The Ichida lab has developed a method to systematically identify new mutations that cause sporadic ALS (PhenoSeq). Detected mutations are studied in-depth in induced motor neurons (iMNs), specifically derived from the patient. We propose the investigation in iMNs of an already identified mutation, which function is closely related to that of the largest genetic contributor of ALS, and its role in ALS. This mutation is in the gene SEC14L5 and has not yet been linked to ALS. Interestingly, besides the detection of a mutation in this gene by the PhenoSeq pipeline, the function of this gene is closely associated to the newly discovered function of the largest genetic contributor to ALS, C9ORF72, also by the host lab. This research will provide a unique analysis of the identified mutation in SEC14L5 and its role in human motor neuron death in ALS, which will increase the understanding of ALS disease mechanisms and facilitate the development of novel therapeutic strategies.

**Palo Alto - Palo Alto Veterans Institute for Research**

**Antoine de Morrée Ph.D.**

**DG**

Towards FSHD Therapeutics: Understanding Polyadenylation Site Choice

|$60,000.00| 8/1/2016 | 7/31/2017 | Year 2
|$60,000.00| 8/1/2017 | 7/31/2018 | Year 3

**Summary**

FSHD (Facioscapulohumeral Muscular Dystrophy) is a muscle disease for which no treatment exists. The disease is caused when muscle cells inadvertently make a toxic protein, called Dux4. There are several steps in the production process of this protein, and in theory at each step there is a possibility to intervene and block production. Such an intervention would stop the muscle from making the toxic protein and gradually allow for detoxification. An essential step towards producing the protein is making stable mRNA. Each mRNA molecule functions as a recipe for making a particular protein. Healthy individuals do not make the Dux4 protein, because they do not make stable mRNA for it. It turns out that FSHD patients have a mutation that allows cells to stabilize those mRNA molecules that are needed to make Dux4 protein. They do so using a process called polyadenylation. Therefore, any intervention that would prevent stabilization of these mRNA molecules would be a potential treatment for FSHD. The goals of the experiments described in this proposal are to understand how cells regulate the polyadenylation of mRNA molecules, and to develop an intervention strategy that would prevent stabilization of only those mRNA molecules needed to make Dux4. We will directly test whether blocking this process leads to a reduction of Dux4. These studies have the potential to lead directly to new treatments that will reduce the toxicity in the muscles of patients with FSHD.

**Thomas Rando M.D., Ph.D.**

**RG**

Non-invasive imaging of disease progression and treatment response in mdx mice
Summary Therapeutics for muscular dystrophies remain largely symptomatic. The use of cell or gene therapy holds the promise of a cure, but there remain many hurdles to translate advances in the laboratory to clinical trials. The main areas of focus of the studies of this proposal are the development of mouse models, so-called "reporter mice", that will be of greatest value for testing cell and gene therapy in terms of altering the progression of the disease. In the initial studies, we will use one of these reporter mice to test for the efficacy of viral gene therapy as means to halt the progression of the disease in the mouse model of Duchenne muscular dystrophy. In a second set of experiments, we will test for the effectiveness of a different reporter mouse strain to provide complementary information about disease progression. Together, the reporter mouse strains will be of tremendous value to the scientific community for testing all kinds of experimental therapeutic approaches for the treatment of muscular dystrophies.

**Palo Alto - Stanford University**  
**Michele Calos Ph.D.**  
**RG16**  
DNA-mediated gene therapy for limb girdle muscular dystrophy  
$100,000.00  
8/1/2016  
7/31/2017  
Year 1  
$100,000.00  
8/1/2017  
7/31/2018  
Year 2  
$100,000.00  
8/1/2018  
7/31/2019  
Year 3

**Summary**  
Muscular dystrophies are caused by mutations in muscle genes. The most direct way to correct muscular dystrophy is to use gene therapy to supply a correct copy of the mutated gene to the affected muscle cells. While viruses are being developed for use in gene therapy, they have many limitations. A simpler alternative that has been shown to be effective in muscle is delivery of “naked” DNA through the bloodstream in such a way that it can enter muscle cells and become permanently incorporated in them. This approach may be especially effective in the limb girdle muscular dystrophies, where a more limited number of muscles need to be treated, and the heart and diaphragm are usually not involved. We will develop an effective DNA-mediated gene therapy method in mouse models of limb girdle muscular dystrophy 2B and 2D, which are deficient in dysferlin and alpha-sarcoglycan proteins, respectively. We possess the necessary mouse models, plasmids, antibodies, and assays and have already verified that gene delivery to limb muscles is effective and genomic integration is beneficial. We will demonstrate improvement in locomotor activity and muscle histology as a result of delivery of the therapeutic genes. This delivery method has been shown to be effective in large animals, so a rapid pathway to the clinic is available following these proof-of-principle studies in disease model mice.

**John West Day MD, PhD**  
**CG**  
International Myotonic Dystrophy Consortium - 11  
$10,000.00  
8/1/2017  
10/1/2017  
Year 1

**Summary**  
The IDMC coordinates clinical, research and treatment development of basic scientists, clinical investigators and industry representatives in the understanding and treatment of myotonic dystrophy. The IDMC organizes meetings of this International Community of investigators in alternate years. The 2017 IDMC meeting is the 11th meeting of this organization, and has been organized around the theme of "Targeting RNA and Entering the Therapeutic Era for Myotonic Dystrophy".

**San Francisco - The Regents of the University of California, San Francisco (Contracts & Grants)**  
**Douglas B Gould Ph.D.**  
**RG**  
Genetic and Pharmacologic Manipulation of COL4A1: Potential Relevance to MDC1A  
$84,600.00  
5/1/2016  
4/30/2017  
Year 2  
$84,600.00  
5/1/2017  
4/30/2018  
Year 3

**Summary**  
We have recently discovered that patients and mice with mutations in the collagen type IV alpha 1 gene (COL4A1) have highly variable neuromuscular disease. Because COL4A1 is a major component of basement membranes we hypothesize that myopathy caused by COL4A1 mutations may be mechanistically similar to myopathy caused by mutations in laminin alpha 2 (LAM2A). LAM2A is another important component of muscular basement membranes and mutations in LAM2A cause MDC1A. In this project we will compare the pathology caused by COL4A1 and LAM2A mutations. Irrespective of the specific outcome, we will seek to identify genetic loci and cellular pathways that modify Col4a1-induced disease and will test the efficacy of bioactive small molecules as potential therapeutic drugs to ameliorate myopathy.

**Daniel Kopinke Ph.D.**  
**DG**  
Ciliary Regulation of Muscle Regeneration
Skeletal muscle has a robust ability to heal after wounds. Muscle repair depends on two distinct stem cells found within the muscle, the satellite cells, which give rise to new myofibers, and the fibro/adipogenic progenitors (FAPs), which coordinate satellite cell behavior. In investigating how FAPs help muscles repair injuries, I discovered that FAPs are the only cells in the muscle that possess primary cilia. Primary cilia are structurally similar to the cilia that propel paramecia through water, but do not move. Instead primary cilia act much like antennas to transmit signals from other cells. The ability of muscle to recover from wounds is compromised with old age and in certain chronic diseases, such as Duchenne muscular dystrophy (DMD). In these conditions, stem cells fail to restore muscle function after injury and the muscle is replaced with fibroblasts and fat. I found that interfering with FAP cilia in mice inhibits the replacement of muscle with fat. This project builds off of these findings to elucidate how cilia control FAP function during muscle injury repair, what signals these cilia sense, and whether I can use drugs to manipulate FAP ciliary signaling to prevent fibrosis and fatty infiltration. This work will illuminate how cilia control stem cell behavior and how ciliary signaling controls FAP function in muscle regeneration. I will use this understanding to assess whether modulating ciliary signaling in FAPs may provide a novel therapy for DMD.

**COLORADO**

**Aurora - University of Colorado Denver, AMC and DC**

**Alexander Polster Ph.D.**

DG16 Structure and Function of Excitation-Contraction Coupling Proteins

$60,000.00  2/1/2017  1/31/2018  Year 1

$60,000.00  2/1/2018  1/31/2019  Year 2

$60,000.00  2/1/2019  1/31/2020  Year 3

**Summary** Electrical signals produced by the nervous system trigger muscle contraction. This process, termed excitation-contraction (EC) coupling, depends on two key proteins: the dihydropyridine receptor (DHPR) which is located in the membrane surrounding the muscle cell, and the type 1 ryanodine receptor (RyR1) located inside the cell. Mutations in these proteins result in serious muscle diseases in humans, including hypokalemic periodic paralysis (HypoPP) and central core disease (CCD). A recently identified adaptor protein (Stac3) plays an important role during muscle development and contributes essentially in signal transmission during EC coupling by binding to the DHPR. In this proposal, by employing a combination of molecular biological, optical and electrophysiological methods we will investigate how the DHPR, RyR1 and Stac3 interact with one another and why mutations cause these human muscle diseases. Information obtained in the course of this study may provide valuable information applicable to the study and treatment of degenerative and episodic muscle diseases.

**Boulder - The Regents of the University of Colorado d/b/a University of Colorado at Boulder**

**Bradley Olwin Ph.D.**

RG15 Enhancing Regeneration to Improve Dystrophic Muscle

$100,000.00  2/1/2016  1/31/2017  Year 1

$100,000.00  2/1/2017  1/31/2018  Year 2

$100,000.00  2/1/2018  1/31/2019  Year 3

**Summary** Skeletal muscle function progressively declines in the majority of muscular dystrophies accompanied a reduction and eventually a failure to regenerate. Exhaustion of muscle stem cell replicative capacity is widely assumed to be responsible for the decline in muscle regeneration despite the lack of data supporting this hypothesis. A cell surface protein that functions as an adhesion receptor (Syndecan-3) appears required to maintain muscle stem cells in their niche or normal home sandwiched between the muscle fiber and connective tissue. When the gene for Syndecan-3 is deleted in the mouse, muscle stem cells leave their niche but are found in the muscle interstitium, where the cells proliferate as myoblasts or muscle progenitor cells. We bred mice lacking the Syndecan-3 gene to mice lacking dystrophin and found that muscle function in resultant mice was dramatically improved, with inflammation and fibrosis reduced and voluntary exercise similar to normal, wild type mice. We believe that the interstitial myoblasts repair dystrophic muscle efficiently ameliorating the dystrophic phenotype and that the muscle stem cells are impaired but not intrinsically defective. We propose to test if inhibition of Syndecan-3 will improve dystrophy other muscular dystrophies and begin to develop therapies to inhibit Syndecan-3.

**Fort Collins - Colorado State University**

**Steven Matthew Markus Ph.D.**
Summary

Intracellular transport is a fundamental and critical process whereby various cargoes are delivered to appropriate sites where they are needed to promote cell growth, maintenance, and division. Defects in this process compromise the survival and maintenance of several cell types, most notably motor neurons that communicate information from the spinal cord to muscles throughout the body, some of which can be as long as one meter. A critical component of the transport machinery is a family of motor proteins that carry cargoes along long polarized filaments called microtubules. One of these motors, dynein, is entirely responsible for the transport of cellular cargo such as organelles and proteins toward the cell center. Mutations in genes that encode dynein components are linked to several types of motor neuron diseases, including spinal muscular atrophy and amyotrophic lateral sclerosis. The underlying defects that give rise to these diseases are not known. This presents a significant barrier to developing effective and targeted therapeutics. The goal of our research is to apply a set of rapid, economical, and rigorous experimental strategies to dissect the molecular basis for dynein dysfunction in various types of motor neuron diseases. In addition to providing valuable insights into the pathology of these diseases, our research will lay the necessary foundation to identify effective, targeted therapies that have the potential to alleviate symptoms in affected patients.

DISTRIBUTION OF COLUMBIA

Washington - Children's Research Institute (CNMC)

Marshall Hogarth Ph.D.

DG16 Targeting the lipid accumulation pathology in LGMD2B

Summary

Limb girdle muscular dystrophy type 2B (LGMD2B) is a progressive muscle wasting disease caused by mutations in the gene coding for dysferlin. Gradual replacement of muscle with fat is a feature of the pathology in both LGMD2B patients and dysferlin-deficient mice. Loss of muscle function in LGMD2B patients and mice is correlated with the fatty conversion of muscle, which suggests that the processes leading to fatty muscle conversion are significant to disease pathogenesis and are thus potential therapeutic targets. However, little is known about the mechanism of the fatty conversion and how the absence of dysferlin disposes muscle into this pathway. Eccentric exercise is known to hasten the disease progression in LGMD2B patients. We have mimicked this process using a muscle injury model which causes fat accumulation selectively in dysferlin-deficient muscle, but not in healthy controls. In this model the extent of fat accumulation is directly proportional to the degree of muscle injury we induce. In parallel, we have also developed a mouse model where age-dependent fat conversion of dysferlin deficient muscle is significantly reduced. This study aims to use the above approach and mouse model we have developed to understand the mechanisms underlying the fat replacement of LGMD2B muscle and identify means to intervene with this mechanism for therapeutic benefit.

James Novak Ph.D.

DG16 Factors that limit exon skipping efficacy in Duchenne muscular dystrophy

Summary

The major challenges facing exon-skipping therapies for Duchenne muscular dystrophy (DMD) are to improve efficiency of delivery of the antisense agents to skeletal/cardiac musculature and to determine the extent of functional improvement achieved by restoration of a given amount of dystrophin. Our current work shows that penetration of morpholino antisense agents is linked to muscle regeneration, a prominent feature of DMD pathology. We show that morpholino primarily localizes within muscle fibers during the brief period of repair when differentiated myogenic cells fuse into them. This prompts us to test whether exercise-induced muscle regeneration improves morpholino uptake and exon skipping. Up to now, work has been limited to the original dystrophic mouse model, whose validity as a preclinical surrogate of DMD is widely debated. We propose to determine how the different disease pathology seen in the DBA/2J-mdx mouse may influence drug uptake, localization and efficacy by comparison with the original Bl10-mdx model. In addition to the morpholino, we propose to investigate the entry of tricyclo-DNA antisense,
another promising exon skipping agent, which we suspect enters by additional or alternative mechanisms. Our comparative experimental design will clarify the various features of disease pathology that contribute to efficient delivery and dystrophin restoration of leading antisense agents in order to improve this valuable therapeutic strategy for DMD.

**Washington - The George Washington University**

**Henry Kaminski MD**

RG16  Targeted Complement Inhibition for Myasthenia Gravis

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$145,841.00</td>
<td>2/1/2017</td>
<td>1/31/2018</td>
<td>Year 1</td>
</tr>
<tr>
<td>$150,206.00</td>
<td>2/1/2018</td>
<td>1/31/2019</td>
<td>Year 2</td>
</tr>
<tr>
<td>$71,140.00</td>
<td>2/1/2019</td>
<td>1/31/2020</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

**Summary** Myasthenia gravis causes severe weakness which may be life-threatening. In the majority of patients antibodies against the acetylcholine receptor and limit nerve-muscle communication by activation of a system called complement. We have a novel technology that inhibits complement only at the nerve-muscle communication point and preserves the role of complement in fighting infections.

**Linda L Kusner Ph.D.**

RG16  INHIBITORS OF APOPTOSIS IN MYASTHENIA GRAVIS.

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$96,426.00</td>
<td>8/1/2016</td>
<td>7/31/2017</td>
<td>Year 1</td>
</tr>
<tr>
<td>$94,655.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td>Year 2</td>
</tr>
<tr>
<td>$96,911.00</td>
<td>8/1/2018</td>
<td>7/31/2019</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

**Summary** Our aim is to develop a therapeutic for myasthenia gravis (MG) which would eliminate the need for corticosteroids, the primary treatment. A central question for MG, and autoimmune disorders in general, is how autoreactive immune cells avoid elimination. We have discovered the presence of an inhibitor of apoptosis protein, survivin, in the thymus and B cells from MG patients. Our hypothesis is that survivin supports the presence of autoreactive immune cells by allowing these cells to escape cell death. By targeting survivin-expressing cells in animal models of MG, we have shown the reduction in acetylcholine receptor antibodies which cause the disease. Our proposal contains two specific aims. The first aim will assess thymus tissue from patients with myasthenia gravis and healthy controls for survivin expression. We will utilize specimens from three centers with large MG populations and the NIH-sponsored MGTX trial. The second aim will evaluate survivin therapeutics in a myasthenia gravis rodent model. The aim will assess the ability for survivin therapeutics to improve observable weakness, decrease the expression of autoreactive immune cells, decrease acetylcholine receptor specific antibodies, and decrease damage to the nerve-muscle junction. Fulfillment of our aims will provide a new fundamental understanding of basic mechanisms of autoimmunity. Successful completion of our studies will validate survivin-targeted approach for therapeutic development.

**FLORIDA**

**Coral Gables - Miller School of Medicine of the University of Miami**

**Michael Benatar Ph.D., M.D.**

CRNG15  Clinical Research in ALS and Related Disorders for Therapy Development (CReATe)

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$150,000.00</td>
<td>3/1/2017</td>
<td>2/28/2018</td>
<td>Year 1</td>
</tr>
<tr>
<td>$150,000.00</td>
<td>3/1/2018</td>
<td>2/28/2019</td>
<td>Year 2</td>
</tr>
</tbody>
</table>

**Summary** During the course of ALS, patients require input and assistance from multiple health professionals, and as a result, multi-disciplinary clinics are, perhaps, the key resource for ongoing management and care. These clinic visits take several hours and substantial clinical data is routinely collected (e.g. neurological examination, ALSFRS-R, quantification of respiratory muscle strength, etc.). Much of this data is identical to the assessments performed at specialized “research visits,” which utilize distinct health record systems and burden patients with profound weakness to attend both clinic and research appointments.

**Gainesville - University of Florida**

**Andrew Berglund Ph.D.**

RG16  Impeding transcription of the toxic RNAs of myotonic dystrophy

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td>Year 1</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2018</td>
<td>7/31/2019</td>
<td>Year 2</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2019</td>
<td>7/31/2020</td>
<td>Year 3</td>
</tr>
</tbody>
</table>
The goal of this research is to develop small molecules that reduce or eliminate the toxic RNA that causes myotonic dystrophy. If successful, this approach can potentially be used in combination with other therapeutic strategies to relieve the suffering of myotonic dystrophy patients.

**Vijayendran Chandran Ph.D**

Integrating omics approaches to identify biomarkers in Friedreich’s Ataxia.

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>2/1/2017</td>
<td>1/31/2018</td>
<td>Year 1</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>2/1/2018</td>
<td>1/31/2019</td>
<td>Year 2</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>2/1/2019</td>
<td>1/31/2020</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Currently, there is no effective approved treatment for Friedreich's ataxia (FRDA). Molecular biomarkers are important to assess clinical trial outcomes, to measure the progression of the disease and to evaluate the most effective therapeutic agents. Currently, there are no high confidence molecular biomarkers associated with FRDA for clinical and preclinical assessment. The absences of good molecular biomarkers in FRDA can be attributed to the non-availability of affected tissues during the earlier and late period of the disease progression. However, utilizing appropriate animal models will provide us the opportunity to identified robust and reproducible biomarkers directly from the tissue that is affected. We have developed an inducible and reversible mouse model for FRDA, which allows us to control the onset and progression of the disease. We were able to reverse the acceleration of disease progression even after significant motor dysfunction was observed. Since, our novel FRDA mouse model exhibits various symptoms parallel to FRDA patients, we plan to screen and identify high confidence prognostic and predictive molecular biomarkers associated with FRDA disease progression.

**Manuela Corti Ph.D**

AAV-mediated Gene Therapy in Friedreich's Ataxia

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$99,617.00</td>
<td>2/1/2017</td>
<td>1/31/2018</td>
<td>Year 1</td>
</tr>
<tr>
<td>$99,817.00</td>
<td>2/1/2018</td>
<td>1/31/2019</td>
<td>Year 2</td>
</tr>
<tr>
<td>$99,520.00</td>
<td>2/1/2019</td>
<td>1/31/2020</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

The objective of this proposal is to develop a treatment strategy for Friedreich’s Ataxia (FA), one of the most common forms of ataxia. Specifically, our research plan focuses on the correction of both the cardiac and neurological degeneration found in the disease. These changes are due to harmful changes in the frataxin gene. Currently, the only treatments available are designed to lessen symptoms and do not address the fundamental cause of FA, which is reduced levels of frataxin. Therefore, the primary objective of this program is to establish a high-impact treatment for FA by correcting the level of frataxin the cell using a vehicle to carry a fully functioning frataxin gene into cells in the heart and nervous system. This proposal will specifically answer important mechanistic questions in a new FA mouse model, which has many of the symptoms of the human patients. First, we will identify the best route of delivery for the frataxin gene in the nervous system by comparing three different strategies for injecting the vector. Second, we will test the safety of repeated delivery of the frataxin gene vector in combination with medications that will prevent reactions against the frataxin protein and the vector components. Completion of this project will be an important milestone in the development of a treatment strategy that will dramatically improve quality of life for FA patients.

**Darin Falk PhD**

Identifying mechanisms of respiratory failure in Pompe disease

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>2/1/2017</td>
<td>1/31/2018</td>
<td>Year 1</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>2/1/2018</td>
<td>1/31/2019</td>
<td>Year 2</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>2/1/2019</td>
<td>1/31/2020</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Pompe disease is a neuromuscular disorder characterized by the inability to break down glycogen in tissue through lack of the enzyme acid alpha-glucosidase (GAA). Subsequent glycogen accumulation ultimately causes muscle function and cardiorespiratory failure before 12 months of age in early-onset patients. A current challenge in developing therapies to treat Pompe patients is lack of a suitable model that accurately reflects the severity of heart and muscle impairment that is displayed in human patients. To enhance our ability to develop impactful therapies, we have recently developed a new rat model of Pompe disease. This model displays the hallmark disease traits with greater resemblance to the human Pompe population. Our initial characterization has determined that severe cardiac and respiratory impairment leads to early mortality in this novel model, and closely mimics the disease in humans. Our goal is to use this advanced model to characterize the mechanisms that lead to cardiorespiratory decline and evaluate the ability of current and emerging therapies to preserve cardiac and respiratory function and improve survival outcomes.
Laura P.W. Ranum Ph.D.,

**RG16** Molecular characterization & antibody therapy in a novel C9orf72 BAC mouse model

$73,356.00  
8/1/2016  
7/31/2017  
Year 1

$73,356.00  
8/1/2017  
7/31/2018  
Year 2

**Summary** There are currently no effective treatment strategies for the large group of neurodegenerative diseases caused by repeat expansions within the human genome. We have discovered a new mechanism by which these disease-causing repeats produce an unexpected and previously unknown category of proteins without using the normal protein production start signal. We have shown the presence of these proteins within human autopsy tissue from patients with the most common cause of familial amyotrophic lateral sclerosis/frontotemporal dementia (C9orf72 ALS/FTD). Additionally we and others have shown that the expanded repeats are made into RNA in both sense and antisense directions in these patients. The goals of this project are to understand when and where these RNA and proteins are produced in ALS/FTD and how they contribute to disease. To accomplish these goals we will use a new mouse model we developed which recapitulates the molecular and disease features of C9-ALS/FTD. We will also test new treatment strategies that target the proteins in the brains of these mice to see if treatments increases survival and decrease disease symptoms. These studies will result in a greater understanding of the mechanisms behind ALS/FTD and may provide new treatments strategies urgently needed for ALS/FTD patients.

Maurice Swanson Ph.D.

**RG16** Novel Mouse Knockin Models for Myotonic Dystrophy

$100,000.00  
2/1/2017  
1/31/2018  
Year 1

$100,000.00  
2/1/2018  
1/31/2019  
Year 2

$100,000.00  
12/1/2019  
1/31/2020  
Year 3

**Summary** The neuromuscular disorder myotonic dystrophy (DM) is the most common form of adult-onset muscular dystrophy. DM is an inherited disease caused by the expansion of DNA simple sequence repeats, or microsatellites, in two different genes, DMPK and CNBP. When transcribed, the resulting repeat expansion RNAs alter the normal functions of the MBNL and CELF RNA binding proteins, which play a central role in developmental gene expression, resulting in the appearance of fetal gene products in adult tissues and disease. A primary goal of the proposed research is to generate and characterize new mouse models for both types of DM (DM1, DM2) to investigate the molecular basis for the clinical differences and similarities observed between these disease forms and to reproduce the multi-system phenotypes of DM1 and DM2. The second objective is to use these DM1 and DM2 mouse models to test a new therapeutic strategy that involves blocking the production of mutant DMPK and CNBP expansion RNAs at the transcriptional level using small molecule drugs, which cross the blood-brain barrier, to reverse the effects of this disease in all tissues, including the central nervous system.

Rebecca Willcocks Ph.D.

**DG** MRI, MRS, and functional characterization of the arm in DMD

$59,964.00  
8/1/2016  
7/31/2017  
Year 2

$55,337.00  
8/1/2017  
7/31/2018  
Year 3

**Summary** Boys and men with Duchenne muscular dystrophy (DMD) experience progressive muscle weakness and difficulty with everyday activities. Many drugs that might slow or reduce the symptoms of DMD are in clinical or preclinical trials. These trials often use walking performance as the most important outcome measure, so boys who are not able to walk are excluded from participation. Boys and men with DMD are unable to walk for a significant part of their life, so it is important to examine whether potential therapeutics can help them to maintain their ability to eat and drink, perform personal care, and use technology, and use a wheelchair. In fact, several biotechnology companies are already working to include arm function measurements in clinical trials. Using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS), we can noninvasively examine how DMD affects the muscles. In this project, we will use MRI and MRS to describe how DMD affects the shoulder, upper arm and forearm muscles of 9-18 year old boys with DMD, and how these muscles change over 1 year. We will also examine the relationship between MRI and MRS measures in the arm muscles and tests of arm function, which will include reaching, grasping, and moving objects. If the MRI and MRS measures are sensitive to the disease and predictive of functional performance, they might be useful to evaluate the impact of drugs in nonambulatory boys and men in clinical trials.

Jacksonville - Mayo Clinic Jacksonville

Tania F Gendron Ph.D.

**RG16** Investigating lymphocyte and spinal fluid c9RAN proteins as c9ALS biomarkers
Summary A C9ORF72 mutation is the most common known cause of amyotrophic lateral sclerosis (ALS), a devastating motor neuron disease. This mutation gives rise to RNA believed to wreak havoc in the brain of “c9ALS” patients. For instance, it causes the production of potentially harmful “c9RAN” proteins. Evidence that this RNA is toxic has spurred the field to investigate therapeutic approaches to counteract it. Yet, success in developing an effective treatment will require all aspects of the drug discovery process to be addressed, including the identification of powerful biomarkers to measure a patient’s response to treatment and to indicate prognosis and disease stage. We reported that poly(GP), an abundant c9RAN protein in c9ALS, is detected in patient cerebrospinal fluid (CSF), and we recently discovered poly(GP) is present in lymphocytes collected from blood. Since poly(GP) is unique to C9ORF72 mutation carriers, and since therapeutic strategies currently under investigation cause decreases in poly(GP), we postulate poly(GP) will serve as important clinical and pharmacodynamic biomarkers. To investigate this, we will take advantage of CSF and lymphocytes collected longitudinally from c9ALS patients as part of a separate study and determine whether poly(GP) associates with clinical features of disease. Furthermore, we will probe the effectiveness of poly(GP) in predicting treatment response using c9ALS patient lymphoblastoid cell lines and CSF from mice engineered to model c9ALS.

Leonard Petrucelli Ph.D.

RG16 Modeling repeat-specific functions and selective vulnerability in C9orf72-ALS

Summary Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease without cure or effective therapeutics. A common cause of this disease is a repeat expansion in the gene C9orf72. This repeat is transcribed into RNA that accumulates into foci throughout the brain and spinal cord. The repeat produces toxic repetitive proteins through a process called RAN translation. And the repeat also leads to the aggregation of a protein called TDP-43 through an unknown mechanism. Interestingly, a similar repeat causes a brain disease called spinocerebellar ataxia type 36 (SCA36). Compared to C9orf72, this repeat also forms foci and some of the same proteins, but does not cause TDP-43 aggregation and affects different neurons. In this study, we aim to compare the effects of expressing the two repeats in mice to determine what cellular functions are affected by the expression of the C9orf72 repeat and not by the SCA36 repeat. We believe these functions will be most important for TDP-43 aggregation and ALS-specific neuronal death. We also wish to explore the effect of expressing the C9orf72 repeat in the cerebellum, a brain region that degenerates in SCA36 but not in ALS. The repeat normally accumulates in this region in patients, and its expression in these neurons may play a role in ALS. Ultimately, if we can understand why neurons respond differently to each repeat, and what induces TDP-43 aggregation, we can use that knowledge to better understand and hopefully treat ALS.

Miami - University of Miami School of Medicine

Antoni Barrientos Ph.D.

RG15 Role of cysteine-rich proteins in mitochondrial cytochrome c oxidase biogenesis

Summary Defects in mitochondrial cytochrome c oxidase (COX) assembly are a frequent cause of mitochondrial encephalomyopathies in humans. This enzyme, formed by multiple proteins, is necessary for cellular respiration and for cellular energy production. COX does its functions thanks to metal groups that are incorporated into two of its proteins. Copper delivery and insertion into COX require COX-specific metallochaperones, COX11 and SCO1/2 that receive copper from COX17, a cysteine-rich protein. Several additional proteins of the COX17 family exist in mitochondria, whose role/s remain unknown. The main objective of this project is to gain insight into the role of three of these proteins: CMC1, CMC2 and PET191. We will use innovative human cultured cell models knockout for these genes, and cell lines from patients with mutations in PET191 and COX copper chaperones to gain insight into the role of CMC1, CMC2 and PET191 in human mitochondrial COX assembly by: (1) Creating and characterizing the phenotype of gene-specific knockout human cells prepared by using innovative gene editing technology. 2) Identifying the proteins that functionally interact with CMC1, CMC2 or PET191, and 3) Analyzing the cellular and
mitochondrial copper levels and the redox environment in the knockout human cell lines as well as in cell lines overexpressing the proteins under study.

GEORGIA

Atlanta - Emory University

Anita Hargrave Corbett Ph.D.

RG16 Understanding Pathology in Oculopharyngeal Muscular Dystrophy (OPMD)

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$99,999.00</td>
<td>8/1/2016</td>
<td>7/31/2017</td>
<td></td>
</tr>
<tr>
<td>$99,998.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td></td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2018</td>
<td>7/31/2019</td>
<td></td>
</tr>
</tbody>
</table>

Summary The goal of this proposal is to understand why there is pathology in specific muscles in the disease, oculopharyngeal muscular dystrophy (OPMD). We have created new mouse models of OPMD to study the disease and optimize therapeutic approaches. In the proposed work, we utilize these mouse models to ask specific questions about why the disease impacts muscle and understand how to best treat patients.

Jonathan D. Glass MD

RRG Clinical Research in ALS (CRIALS)

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$155,491.00</td>
<td>1/1/2017</td>
<td>12/31/2017</td>
<td></td>
</tr>
</tbody>
</table>

Summary Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease with wide variability in clinical features. This variability includes age of onset, rate of progression, and degree of disability, leading clinicians and investigators to question whether ALS represents a disease with a number of underlying mechanisms and causes. Our clinical center has expertise in clinical characterization of patients, collection of biospecimens (blood, DNA, spinal fluid, and autopsy tissues), and correlation and databanking of clinical information. These data and biospecimens are essential building blocks for research into pathogenesis and treatment of ALS. We share these materials with investigators around the world. This proposal is to provide funding for the infrastructure needed to maintain and grow this valuable resource of ALS research.

ILLINOIS

Champaign - The Board of Trustees of the University of Illinois at Urbana-Champaign

Auinash Kalsotra Ph.D.

RG16 Elucidating the molecular basis for cardiac dysfunctions in Myotonic Dystrophy

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td></td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2018</td>
<td>7/31/2019</td>
<td></td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2019</td>
<td>7/31/2020</td>
<td></td>
</tr>
</tbody>
</table>

Summary Myotonic dystrophy type I (DM1) is caused by an unusual mutation in which a small DNA segment of the mutated gene is repeated hundreds of times. The mutated gene, when copied into RNA, becomes toxic and particularly harmful because instead of its normal exit to the cytoplasm, the RNA with repeats gets trapped within the nucleus, which alters the normal function of many genes, not just the gene with the mutation. While the mutation affects multiple tissues, cardiac defects are the second leading cause of death amongst DM1 individuals; however, the molecular mechanism(s) responsible for the cardiac pathogenesis remain poorly understood. We have found that in DM1 diseased heart, the fetal non-muscle isoform of a previously unrecognized RNA binding protein is significantly up regulated. By forcing the expression of the non-muscle isoform of RBFOX2 in wildtype adult mouse heart, we have reproduced most of the cardiac dysfunctions observed in DM1, including arrhythmias and cardiac conduction defects. In this proposal, we will determine how the balance between muscle and non-muscle isoforms for RBFOX2 is achieved during normal heart development. We will further investigate how this regulation is disrupted in DM1 and why the selective expression of non-muscle RBFOX2 isoform triggers a cardiac disease phenotype. We will use newly generated mouse models, in vitro cell culture systems, and genome-wide approaches to answer these exciting questions.

Chicago - Ann & Robert H. Lurie Children's Hospital of Chicago

Christine DiDonato PhD

RG16 Deciphering mechanisms underlying muscle dysfunction in SMA mice

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>8/1/2016</td>
<td>7/31/2017</td>
<td></td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td></td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2018</td>
<td>7/31/2019</td>
<td></td>
</tr>
</tbody>
</table>
SMA is caused by low levels of the ubiquitously expressed protein, survival motor neuron (SMN). We have developed long-lived SMA mice in which we have specifically increased SMN in motor neurons. These mice have normal functioning motor neurons, but they still have very clear functional deficits, thus unmasking muscle problems caused by low SMN levels in this tissue. This has important long-term implications for SMN-based therapies under current clinical investigation. Here we will characterize these muscle defects, identify altered molecular pathways in skeletal muscle that are responsible for the observed muscle weakness and atrophy and based or future research aimed at enhancing muscle function and preservation.

Evangelos Kiskinis PhD.

RG15  
Defining the overlap of molecular mechanisms of degeneration in genetic ALS

$100,000.00  2/1/2016  1/31/2017  Year 1
$100,000.00  2/1/2017  1/31/2018  Year 2
$100,000.00  2/1/2018  1/31/2019  Year 3

Summary We have successfully been using stem cells generated from the skin of ALS patients to make patient-specific human motor neurons and study their disease in the lab. This novel technology has essentially given us access inside the brain and spinal cord of patients. We have shown that motor neurons with mutations in the SOD1 gene exhibit mitochondrial dysfunction and electrical excitability defects. We have also shown that using small molecules that target these pathways we can extend the survival of patient motor neurons. In this study we propose to extend this approach and generate motor neurons from patients that from a wide range of different genetic ALS types. By studying these different motor neurons and comparing how similar they are in terms of the disease mechanisms we can understand how similar or different ALS patients might be. This will be invaluable in our efforts to: a) design drugs that will target specific patients; b) as well as to identify therapeutics that might be broadly relevant to all ALS patients. In the second part of our proposal we will determine whether the irregular manner in which ALS motor neurons fire electrical signals might contribute to their death. This is an important question as work done in our cellular system as well as in human patients has shown that this is a consistent problem that may significantly contribute to the disease. If we understand why it happens and how motor neurons deal with it we might discover ways of stopping it.

Mattia Quattrocelli Ph.D.

DG16  
Glucocorticoids in fiber repair and regeneration of dystrophic muscles.

$60,000.00  2/1/2017  1/31/2018  Year 1
$60,000.00  2/1/2018  1/31/2019  Year 2
$60,000.00  2/1/2019  1/31/2020  Year 3

Summary Muscular dystrophies are characterized by chronic disruption of muscles, with consequent wasting of muscle. Normally, in response to muscle injury that disrupts the membrane around muscle, there is a repair complex that seals the damage. In dystrophic muscle, however, this process is impaired and in addition, dystrophic muscle do not regenerate as well as normal muscles. At present, glucocorticoid steroids are the only pharmacological treatment for Duchenne Muscular Dystrophy. However, the side effects are prominent and the role of glucocorticoids on the actual fiber repair process is still unknown. Moreover, the effects of glucocorticoids on the stem cells in muscle are not well studied. With this project, we aim to define the effects of glucocorticoids on muscle membrane repair and regeneration in dystrophic muscles using newly developed methods. We will first test the effects of pulsed and chronic administration of glucocorticoids on fiber repair and resident stem cells of dystrophic muscles. We will then examine how glucocorticoids counteract the negative effects of the TGFβ molecular pathway on muscle repair and regeneration. Finally, we will study how glucocorticoids and the novel genetic modifier Jagged converge towards beneficial effects on dystrophic muscles.

INDIANA

West Lafayette - Purdue University

Feng Yue Ph.D.

DG16  
Therapeutic Potential of Pten Inhibition in Duchenne Muscular Dystrophy

$58,074.00  8/1/2017  7/31/2018  Year 1
$58,285.00  8/1/2018  7/31/2019  Year 2
$59,050.00  8/1/2019  7/31/2020  Year 3

Summary Duchenne muscular dystrophy (DMD) is a genetic disorder caused by an absence of dystrophin, a protein that helps keep muscle cells intact. In DMD, the muscle is more susceptible to injury but cannot keep up
with repair, which eventually leads to muscle loss and weakness. The study in present proposal aims to
develop potential therapies that promote regrowth of dystrophic muscle and, in turn, increase muscle
strength. The strategy we developed involves inhibiting the action of a natural protein called phosphatase
and tensin homolog (PTEN) that limits muscle cell growth. In healthy muscle, the level of PTEN is very low,
but becomes very high in DMD muscles. Notably, lowering PTEN in healthy muscle is sufficient to allow
muscle grow larger and stronger. Using a preclinical mouse model of DMD, we will first study whether
inhibiting PTEN by genetic deficiency of PTEN gene in muscle cells could boost muscle growth, increase
muscle strength in DMD mice. Moreover, we will develop a safe, high-efficiency pharmacological approach
to specifically deliver a well-known Pten inhibitor to the skeletal muscle of DMD mice, and examine its effect
on muscle functional recovery. These studies may lead to the development of novel therapeutic strategies
for clinical treatment of DMD.

IOWA
Iowa City - The University of Iowa
Michael Shy M.D.

<table>
<thead>
<tr>
<th>RIG</th>
<th>Inherited Neuropathy Consortium</th>
<th>$159,733.00</th>
<th>2/1/2016</th>
<th>1/31/2017</th>
<th>Year 1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$161,796.00</td>
<td>2/1/2017</td>
<td>1/31/2018</td>
<td>Year 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$157,270.00</td>
<td>2/1/2018</td>
<td>1/31/2019</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Summary The Inherited Neuropathy Consortium (INC) is an international consortium of centers funded by the MDA
and NIH devoted towards developing treatments for and treating patients with inherited peripheral
neuropathies known as Charcot Marie Tooth disease (CMT). Over seven thousand participants are registered
in various INC protocols that investigate how different types of CMT progress, develop outcome measures in
children and adults to be used in clinical trial development, identify genetic changes that modify the
severity of CMT, and identify new genetic causes of CMT. We also are training the next generation of
researchers in CMT, developing standards of care for people with CMT, developing clinical trials and linking
with National CMT programs throughout the world.

Lori L. Wallrath Ph.D.

<table>
<thead>
<tr>
<th>RG16</th>
<th>Suppression of lamin-induced muscle defects</th>
<th>$94,226.00</th>
<th>2/1/2017</th>
<th>1/31/2018</th>
<th>Year 1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$95,172.00</td>
<td>2/1/2018</td>
<td>1/31/2019</td>
<td>Year 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$95,856.00</td>
<td>2/1/2019</td>
<td>1/31/2020</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Summary Mutations in the human LMNA gene cause several types of muscular dystrophy, including Emery-Dreifuss
muscular dystrophy. These diseases are characterized by restricted movement of the joints (elbows, ankles
and neck), muscle weakness and wasting (especially of the upper arms and lower legs), and heart
problems. There are currently no treatments for these types of muscular dystrophy. Our goal is to identify
potential treatments. We are using the powerful genetics of a model organism (fruit fly) to identify potential
drug targets. Our preliminary data show that we can restore muscle function in a fruit fly model of Emery-
Dreifuss muscular dystrophy, demonstrating feasibility of this approach. We will test potential therapeutic
drugs on the fruit fly model and on patient-derived cell cultures. Collectively, our studies will identify
potential drug targets and test drugs that are predicted to restore muscle function based on our findings.

KENTUCKY
Lexington - University of Kentucky Research Foundation

Haining Zhu Ph.D.

<table>
<thead>
<tr>
<th>RG</th>
<th>FUS phosphorylation and its significance in ALS</th>
<th>$100,000.00</th>
<th>8/1/2016</th>
<th>7/31/2017</th>
<th>Year 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$100,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Summary Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disease. Several ALS genes
have been identified, including two genes encoding RNA processing proteins TDP-43 and fused in sarcoma
(FUS). FUS is a ubiquitously expressed RNA-binding protein that is predominantly localized in the nucleus.
FUS plays a role in a variety of processes including transcriptional regulation and mRNA splicing. However,
little is known regarding how FUS function is regulated. The hypothesis to be tested is that phosphorylation
of FUS by CK2 plays a critical role in regulating FUS function and that inhibition of FUS phosphorylation can
mitigate its toxicity. We recently found that FUS is phosphorylated by casein kinase 2 (CK2) and identified
several potential phosphorylation sites. Co-expression of CK2 exacerbated the locomotive impairment of
FUS transgenic flies whereas the CK2 phosphorylation-deficient mutant of FUS reduced toxicity in flies. The
results suggest that phosphorylation of FUS by CK2 can directly modulate FUS toxicity. We will determine the effect of inhibiting FUS phosphorylation on FUS toxicity in vivo using fly models. We will determine the exact CK2 phosphorylation site(s) using mass spectrometry and investigate the significance of individual phosphorylation site. This project will not only yield novel mechanistic insights on regulation of FUS function by CK2 phosphorylation, but also determine whether CK2 inhibition can be a new therapeutic avenue.

MAINE

Bar Harbor - The Jackson Laboratory

Robert W. Burgess Ph.D.

RG Gene therapy approaches for Charcot-Marie-Tooth type 2D

$100,000.00 8/1/2016 7/31/2017 Year 2

$100,000.00 8/1/2017 7/31/2018 Year 3

Summary Charcot-Marie-Tooth disease (CMT) is a clinically and genetically heterogeneous collection of conditions that result in fatigue and weakness due to degeneration of nerves in the arms and legs. There is currently no treatment for CMT. Using well-validated mouse models of CMT type 2D, caused by dominant mutations in the GARS gene (glycyl tRNA synthetase), we will perform a proof-of-concept gene therapy experiment. We will target the mutant copy of the Gars gene while leaving the normal copy intact, with the anticipation that this will result in an effective treatment for the neuropathy. Positive results from these studies will have important translational implications not only for CMT2D and related peripheral neuropathies, but also for many dominantly inherited neuromuscular diseases, including muscular dystrophies and motor neuron diseases. The successful completion of these studies will enable us to develop gene therapy approaches for human GARS CMT2D variants.

MARYLAND

Baltimore - Johns Hopkins University School of Medicine

Mohamed H. Farah PhD

RG16 Mechanisms of neuromuscular synapse plasticity induced by BACE1 inhibition

$100,000.00 2/1/2017 1/30/2018 Year 1

$100,000.00 2/1/2018 1/30/2019 Year 2

$100,000.00 2/1/2019 1/30/2020 Year 3

Summary Strategies aimed at promoting motor axon sprouting and functional restoration by reinnervation might be useful to treat motor neuron diseases. We previously discovered that knockout of beta secretase (BACE1), an enzyme that proteolytically processes amyloid precursor protein (APP), enhances peripheral nerve regeneration following sciatic nerve crush injury in mice. This prompted us to explore the possibility that pharmacological inhibition of BACE1 might be an effective means to encourage collateral sprouting of intact motor axons at an early stage of motor neuron disease. This possibility is attractive, given that the pharmaceutical industry is actively developing BACE1 inhibitors as candidate therapies for Alzheimer's disease, and is therefore amassing safety, efficacy, and biodistribution data on these molecules. Here, we present preliminary data to suggest that a small-molecule BACE1 inhibitor improves motor axon sprouting and restores nerve function in SOD1 mice, an aggressive model of motor neurons disease.

Jeffrey D. Rothstein M.D., Ph.D.

RG C9orf72 ALS is caused by nuclear-cytoplasmic trafficking dysfunction

$100,000.00 8/1/2016 7/31/2017 Year 2

$100,000.00 8/1/2017 7/31/2018 Year 3

Summary A mutation of the gene C9orf72mutation is the most common genetic cause of familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), though the underlying disease mechanism is poorly defined. Furthermore, is turns out to be a cery common caus eof apparent sporadic ALS, in spite of not prior family history. This discovery herald a huge change in ALS biology and understanding the nature of the biological defect is essential to pioneer new approaches to ALS and most important develop a therapy that will affect c very substantial subset of ALS. Our past failure in finding ALS therapies can and will be overcome by understanding these molecular sub-forms of ALS. This proposal will set the stage for such discoveries.

Jeffrey D. Rothstein M.D., Ph.D.

RRG Robert Packard Center for ALS Research (Wings 2015) (Rothstein, JD)

$70,191.95 2/1/2017 1/31/2018 Year 1
Summary
MDA funding received (as designated by Wings Over Wall Street) will be used to fund one (1) collaborative research project through the Robert Packard Center for ALS Research at Johns Hopkins. This project is affiliated with a Hopkins-based researcher who will participate in the Packard Center's collaborative process and whose proposal has been reviewed and approved by the Center's scientific advisory board. Any additional funding required for this project beyond that awarded by MDA's designated grant will be covered by the Packard Center. Money received from this MDA designated grant will not be used to support Dr. Rothstein or his lab.

Baltimore - Johns Hopkins University - School of Medicine
Constantin d’Ydewalle Ph.D.

DG
LncRNA as therapeutic target for SMA
$60,000.00 8/1/2016 7/31/2017 Year 2
$60,000.00 8/1/2017 7/31/2018 Year 3

Summary
Spinal muscular atrophy (SMA) is the leading inherited cause of infant mortality and is caused by mutation of the survival motor neuron-1 gene (SMN1), retention of a highly homologous SMN2 gene, and reduced levels of SMN protein. Hence, SMA treatments currently under development aim to increase SMN protein levels. Prior studies and our preliminary data show that SMN is highly expressed during early gestational stages, but decreases postnatally. This may indicate that specific levels of SMN are temporally required for normal motor neuronal development. It is unknown, however, how SMN expression is regulated over time. Approximately 90% of the human genome is transcribed while only 2% has protein-coding potential. Recently, long non-coding RNAs (lncRNAs) have been shown to be powerful regulators of gene expression. LncRNAs transcriptionally regulate many genes via interactions with the polycomb repressive complex-2 (PRC2). My work focuses on a SMN-associated lncRNA that regulates the expression of SMN during neuronal development and differentiation. The project proposed here aims to understand how this mechanism works in neurons both in mice and in a petri dish. A better understanding of the mechanisms that regulate SMN expression are crucial for SMA therapeutics development.

Thomas Philips Ph.D.

DG15
The role of monocarboxylate transporters in motor neuron disease
$60,000.00 2/1/2016 1/31/2017 Year 1
$60,000.00 2/1/2017 1/31/2018 Year 2
$60,000.00 2/1/2018 1/31/2019 Year 3

Summary
Motor neuron degenerative diseases like amyotrophic lateral sclerosis (ALS) are characterized by the progressive degeneration of the motor neuron, the cells that control voluntary movement by acting on specific muscle subtypes. In ALS patients, degeneration of motor neurons leads to muscle wasting, spasticity, paralysis and death approximately three to five years after disease onset. No cure for this disease is currently available. One of the hallmarks of motor neuron degeneration is the reduced trophic support in terms of energy metabolites provided to the motor neuron by cells that support its function, the glial cells. It has recently been established that one glial cell type, the oligodendrocyte (oligo), is involved in providing motor neurons with energy metabolites. Oligos are ideally suited for this role given their strong intimacy with the motor neuron as these cells entirely engulf the motor neuron axon. Specific oligo transporters, the monocarboxylate transporters, mediate the transfer of energy metabolites from oligo into neurons. As motor neurons can be as long as four feet in humans, motor neurons are a huge burden on the energy supply available in order to maintain normal homeostasis. In this study, we try to obtain a better understanding of the oligo trophic support to the motor neuron and assess whether we can modulate it in order to prevent motor neuron degeneration.

Baltimore - Johns Hopkins University
Jiou Wang Ph.D.

RG16
Novel Quality Control Pathways in ALS
$100,000.00 2/1/2017 1/31/2018 Year 1
$100,000.00 2/1/2018 1/31/2019 Year 2
$100,000.00 2/1/2019 1/31/2020 Year 3

Summary
We have found potential drug targets that need to be evaluated to determine their effectiveness in treating proteotoxicity-related neurodegeneration in ALS. The rationale for this proposal is based on the strong evidence of a tight link between ALS pathogenesis and protein quality control. Diverse forms of ALS are increasingly being connected with failed protein quality control in the nervous system. The research proposed here, if successful, will lead to new therapeutic agents that can help to treat both familial and sporadic patients of amyotrophic lateral sclerosis. Instead of targeting a specific disease protein, we hope to
develop a “wide-spectrum” therapeutic strategy that could have a broad impact on the majority of ALS patients.

**Baltimore - University of Maryland, Baltimore**

**Aikaterini Kontrogianni-Konstantopoulos Ph.D.**

**RG**

Loss of actomyosin regulation in distal arthrogryposis due to mutant MyBP-C slow

$100,000.00 8/1/2016 7/31/2017 Year 2

$100,000.00 8/1/2017 7/31/2018 Year 3

**Summary**

Contraction of skeletal muscle is a highly regulated process, which involves the sliding of thin actin filaments past thick myosin filaments. When this process is compromised, skeletal myopathies arise with symptoms that may vary from mild to severe, resulting in muscle weakness and potentially death. Myosin binding protein-C (MyBP-C) comprises a family of important regulators of muscle contractility, and is expressed in both skeletal and cardiac muscles. Consistent with this, mutations in the genes encoding the cardiac and slow skeletal isoforms have been causally linked with the development of hypertrophic cardiomyopathy and arthrogryposis myopathy, respectively. Our studies will focus on the characterization of the physiological roles of the slow isoform of MyBP-C in skeletal muscle during normalcy, and how these are compromised in severe and lethal forms of arthrogryposis myopathy. The obtained information will provide important mechanistic insights about the molecular mechanisms that regulate contraction in health, and how these are altered during disease.

**MASSACHUSETTS**

**Boston - Children’s Hospital Boston**

**Alan H. Beggs Ph.D.**

**RG15**

Molecular Genetics of Congenital Myopathies

$100,000.00 2/1/2016 1/31/2017 Year 1

$100,000.00 2/1/2017 1/31/2018 Year 2

$100,000.00 2/1/2018 1/31/2019 Year 3

**Summary**

The congenital myopathies are a diverse group of inherited neuromuscular conditions that result in skeletal muscle weakness of variable onset and severity. To better understand the causes of these disorders, which are commonly seen in MDA neuromuscular clinics, we are building an extensive registry and biorepository of cases and specimens from patients and their families. Through new genetic methods such as “whole exome sequencing” of patient’s DNA, we are completing the identification of disease genes and genetic mutations that has been ongoing since the 1980’s. To study the pathophysiology and provide model systems with which to develop therapies, we are developing zebrafish, mouse and dog models of these mutations. The zebrafish models are particularly powerful as they provide us with the opportunity to screen small molecule libraries to identify new drugs to treat these conditions. In this project we will continue and expand this work to focus on the less well-understood congenital myopathies that are often undiagnosed due to ambiguous results on clinical muscle biopsy. Success will lead to a better understanding of the causes of weakness in congenital myopathies, and to the development of new drug therapies to treat these conditions.

**Emanuela Gussoni Ph.D.**

**RG16**

Tetraspanin CD82 in dystrophic satellite cells

$99,253.00 2/1/2017 1/31/2018 Year 1

$98,937.00 2/1/2018 1/31/2019 Year 2

$99,795.00 2/1/2019 1/31/2020 Year 3

**Summary**

Dystrophic muscle stem cells are thought to be continuously active in an attempt to repair damaged myofiber due to lack of dystrophin and/or its associated proteins. We recently identified a novel cell surface marker for muscle stem cells in human and mouse muscle, named CD82. CD82 is expressed in human muscle satellite cells, both quiescent and activated. Importantly, CD82 protein expression is reduced in human DMD and in dystrophic mdx5cv mouse muscles. This application proposes to study the function of CD82 in muscle stem cells and understand how the decreased expression of this protein in dystrophic cells is linked to the disease progression. More importantly, the proposed studies will provide the groundwork for developing future therapies aimed at boosting expression of CD82 as a way to stabilize the sarcolemma and muscle stem cell function in dystrophic muscle.

**Louis Kunkel Ph.D.**

**RG15**

Genome-scale CRISPR-Cas9 knockout screen to identify genetic modifiers of FSHD
FSHD is the most common autosomal dominant form of muscular dystrophy, yet the underlying genetics is not completely solved. We propose to perform a genetic screening experiment to identify the missing genetic link(s) that may hold answers as to why some individuals that harbor FSHD genetics are not clinically affected, and why individuals with the same disease genetics are differently affected. Using the latest in genome-editing technology, we will perform genome-wide modifications that result in loss-of-function mutations across every gene in the human genome, systematically identifying modifier genes that reduce the phenotypic impact of FSHD when inactivated. Our candidate modifier genes will be cross-referenced to a panel of genomic sequencing data from asymptomatic individuals. We will further validate these genes with functional rescue experiments in our zebrafish model of FSHD, and measure their ability to change the molecular disease signature of FSHD patient cells. Ultimately, we seek to exploit the existence of so-called ‘cured’ or mildly affected human models of FSHD as a resource to aid in our understanding of FSHD disease genetics, as well as pinpoint concrete targets for drug discovery.

Angela Lek Ph.D.

Identifying genetic modifiers of FSHD

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$60,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td>Year 1</td>
</tr>
<tr>
<td>$60,000.00</td>
<td>8/1/2018</td>
<td>7/31/2019</td>
<td>Year 2</td>
</tr>
<tr>
<td>$60,000.00</td>
<td>8/1/2019</td>
<td>7/31/2020</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Mitochondrial diseases are a heterogeneous class of conditions, mostly cause by mutations, that severely impair energy production. As a consequence, high-energy demanding tissues such as brain, heart and skeletal muscle are primary affected. Clinically, based on the severity of the cells and tissues affected, the symptoms are muscle weakness and pain/myopathies, loss of motor control, cardiac and liver diseases, seizures, visual/hearing problems, lactic acidosis and developmental problems. As it relates to treatments and therapies, at this time there are no cures for mitochondrial diseases. Thus, treatments are more often palliative and mainly include vitamin cofactors, nutritional manipulations, and exercise. Taken together the facts indicated above, this application proposes to investigate this medical urge by using a combination of genetic and chemical screens to identify novel targets to combat mitochondrial diseases. Interestingly, using this technology we identified an FDA-approved drug that is able to enhance the mitochondrial function in cells derived from patients carrying mitochondrial mutations. These cells are unable to generate enough energy to survived a die. Surprisingly, treatment with the discovered compound proved to be beneficial and energy production was partially restored, leading to cell survival. We aim to characterize the effects of this drug and further investigate whether it might be use in future therapies to combat mitochondrial disorders.

Boston - Harvard Medical School

Identifying genetic modifiers of FSHD

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$60,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td>Year 1</td>
</tr>
<tr>
<td>$60,000.00</td>
<td>8/1/2018</td>
<td>7/31/2019</td>
<td>Year 2</td>
</tr>
<tr>
<td>$60,000.00</td>
<td>8/1/2019</td>
<td>7/31/2020</td>
<td>Year 3</td>
</tr>
</tbody>
</table>
Alfred L. Goldberg Ph.D.

RG16  Protein breakdown in muscle in normal and disease states
$100,000.00  8/1/2016  7/31/2017  Year 1
$100,000.00  8/1/2017  7/31/2018  Year 2
$100,000.00  8/1/2018  7/1/2019  Year 3

Summary One major objective of our work is to clarify the molecular mechanisms for the muscle atrophy that occurs with congenital myopathies, neuronal disease (e.g. ALS), and many systemic diseases, in order to lay the basis for development of rational therapies. Our early work established that this debilitating loss of muscle mass is due primarily to excessive degradation of muscle proteins, and recently we identified key enzymes that mark muscle proteins for destruction during atrophy. In recent years, much has been learned about the proteasome, the molecular machine that degrades most cell proteins. We recently found that during atrophy the composition of proteasomes changes in ways that seem to contribute to the accelerated protein destruction. The proposed studies will explore the special features of proteasomes in atrophying muscle and their importance in disease states. Many muscle diseases are caused by the accumulation in muscles of aggregates of misfolded, mutated proteins, which normally are efficiently degraded by proteasomes. We recently found that the capacity of proteasomes to destroy such abnormal, toxic proteins can be enhanced by drugs that induce the phosphorylation of a key component of the proteasome. We will test whether this newly discovered method to activate the proteasomes might be useful in promoting the clearance of these toxic proteins and thus slow progression of these various diseases, for which, no effective treatment is known.

Boston - Massachusetts General Hospital (The General Hospital Corp.)

Monkol Lek PhD

DG15  Improving the diagnosis of neuromuscular diseases
$59,873.00  2/1/2016  1/31/2017  Year 1
$59,873.00  2/1/2017  1/31/2018  Year 2

Summary We now live in a golden period for genetic disease diagnosis where advances in DNA sequencing technology has dramatically accelerated the diagnosis of neuromuscular diseases (NMD), reducing diagnosis time from years to a matter of a few weeks. Rapid diagnosis is critical for families affected by these severe diseases, allowing them to make important decisions about family planning, delaying disease progression, and to decide on therapeutic options. The majority of disease causing mutations are discovered in protein-coding regions (known collectively as the exome), but current exome approaches have a diagnosis rate of just 40%. We aim to increase the diagnosis rate through inspecting regions outside the exome using whole-genome sequencing. In addition, we will use RNA sequencing to gain direct insight into the functional impact of DNA changes on muscle function. Finally, we will leverage an unprecedented collection of over 60,000 sequenced control samples to improve methods for identifying which of the millions of variants in a patient’s DNA are most likely to cause their disease, and to minimize the risk of false diagnoses. We will apply this approach to a cohort of over 1000 individuals from families with neuromuscular diseases. The identification of novel NMD genes will provide deeper understanding of common disease mechanisms. Future treatment can then be prioritize to target common mechanisms such that it can benefit a larger number of patients.

Thurman Wheeler M.D.

RG16  Extracellular RNA as biomarkers of myotonic dystrophy
$110,000.00  2/1/2017  1/31/2018  Year 1
$110,000.00  2/1/2018  1/31/2019  Year 2
$110,000.00  2/1/2019  1/31/2020  Year 3

Summary A new drug for treatment of myotonic dystrophy type 1 is being tested in clinical trials. Monitoring drug effects currently requires that patients undergo multiple muscle biopsies, a procedure that is invasive, painful, and, in pediatric patients, requires general anesthesia. The goal of this project is to develop biomarkers in human urine or blood that 1) will reduce or eliminate the need for muscle biopsies to determine whether treatments are working, 2) can be measured multiple times as needed during the trial, and 3) enable inclusion of children with myotonic dystrophy in upcoming trials. Our approach will be applicable to many different treatment strategies for both myotonic dystrophy types 1 and 2, and extend to other muscular dystrophies.

Boston - Northeast ALS Consortium

Jonathan D. Glass MD
RIG Northeast ALS Consortium: Infrastructure support

$51,500.00 9/1/2016 8/31/2017 Year 2
$53,045.00 9/1/2017 8/31/2018 Year 3

Summary
The Northeast ALS Consortium (NEALS) is an international, independent, non-profit group of 117 research sites around the world who collaboratively conduct clinical research in Amyotrophic Lateral Sclerosis (ALS) and other motor neuron diseases. The mission of NEALS is to translate scientific advances into new treatments for people with ALS and motor neuron disease as rapidly as possible. This proposal is for support of the administrative infrastructure necessary for the functioning of NEALS. Administrative funding will be shared equally with a grant from the ALS Association.

Lexington - Izumi Biosciences Inc.
Antonius (Ton) Martinus Bunt M.D.

MVP15 IZ10023 inhibits two efflux pumps and enhances riluzole efficacy in ALS

$56,400.00 1/1/2017 1/30/2017 Year 1
$28,560.00 2/1/2017 2/1/2018 Year 2
$11,400.00 2/2/2018 7/1/2018 Year 3

Summary
ALS is a rapidly progressive, lethal neurodegenerative disease where patients experience a transient benefit from riluzole, the only approved drug. In early stage, riluzole slows disease progression, whereas this benefit is lost in late stage. Two pumps (P-gp and BCRP) were over expressed locally in diseased spinal cords of ALS patients. We believe they collaborate to remove riluzole, cause ineffective local drug levels, and a loss of efficacy of riluzole. Elacridar is a potent, selective inhibitor of both pumps. Elacridar selectively targeted drug distribution to the pump-protected brain, with levels in plasma and peripheral organs relatively unchanged. In ALS mice, elacridar enhanced riluzole activity, and significantly prolonged survival. In six Phase I studies with 97 patients, oral elacridar was safe and well tolerated, yet did not reach required plasma levels. Izumi developed oral IZ10023 with greatly improved plasma levels. The 1.5 year project seeks to 1. test the effect of IZ10023 on riluzole brain levels in rodents, 2. manufacture drug supplies for animal and patient studies, 3. conduct FDA-mandated safety studies in animals, 4. open an IND. In subsequent studies we seek to confirm that IZ10023 enhances riluzole efficacy while maintaining safety in ALS patients. The pump blocker IZ10023 may remove a key obstacle to effective drug therapy, and provide a foundation for future drug combinations to further improve the outcomes for ALS and possibly Alzheimer patients.

Waltham - PerkinElmer Genetics, Inc.
Madhuri R Hegde B.S, M.S, Ph.D

RG16 Precision medicine in muscular dystrophy: Variants of unknown significance

$100,000.00 8/1/2016 7/31/2017 Year 1
$100,000.00 8/1/2017 7/31/2018 Year 2
$100,000.00 8/1/2018 7/31/2019 Year 3

Summary
Gene panels, exome and genome sequencing are now widely used in clinical diagnostics for neuromuscular disorders. These DNA based assays result in detection of a large number of variants of unknown clinical significance (VOUS). According to the recent variant interpretation guidelines, several pieces of data including functional evidence are needed to classify the variant of unknown significance (VOUS) as being pathogenic or not. Transcriptome analysis can be used for functional assessment of these variants to generate evidence for pathogenicity for variant in known and newly identified and therefore help patients participate in clinical trials and drive precision genomic medicine for neuromuscular disorders.

Worcester - University of Massachusetts Medical School
Charles P. Emerson Ph.D.

RG16 iPSC-induced skeletal muscle progenitors to study human myogenesis and FSHD

$100,000.00 2/1/2017 1/31/2018 Year 1
$100,000.00 2/1/2018 1/31/2019 Year 2
$100,000.00 2/1/2019 1/31/2020 Year 3

Summary
Human induced pluripotent stem cells (hiPSCs) are produced by reprogramming adult cells (for example, skin cells) to become embryonic-like cells that can be turned into any cell type (i.e. are pluripotent) and grow indefinitely in tissue culture. The Emerson lab, together with their collaborators, have developed novel methods to induce hiPSCs to produce skeletal muscle cells that differentiate in cell culture and can be xeno-
engrafted into mouse muscles where they differentiate into muscle fibers, allowing them to investigate how muscle diseases form and progress. We are studying facioscapulohumeral muscular dystrophy (FSHD), a disease of progressive muscle weakness, using hiPSC models. FSHD patient-derived hiPSCs induced to skeletal muscle express the FSHD disease gene, DUX4, and other biomarkers, both in cell culture and xenograft muscle, establishing that our hiPSC myogenesis system can model FSHD molecular pathology. We propose to utilize hiPSC myogenesis to investigate FSHD disease mechanisms in muscle cell and engraftment models using hiPSCs from FSHD patients with infantile/early onset, adult onset, and non-manifesting disease. Our findings will inform us about the contributions of FSHD disease genes and epigenetic dysregulation to FSHD clinical disease severity and muscle pathology and identify new drug targets for therapeutics.

Fen-Biao Gao Ph.D. 1995

**RG16**

**Investigation of DNA damage as a therapeutic target in C9ORF72-related ALS**

- $100,000.00 2/1/2017 1/31/2018 Year 1
- $100,000.00 2/1/2018 1/31/2019 Year 2
- $100,000.00 2/1/2019 1/31/2020 Year 3

**Summary**

C9ORF72 repeat expansion is the most common genetic mutation in ALS. To understand its pathogenic mechanisms, we generated induced pluripotent stem cells (iPSCs) from C9ORF72 patients and differentiated them into motor neurons and cortical neurons that recapitulate some key neuropathological features, such as abnormal accumulation of RNA “clumps” and production of unusual toxic protein species (Almeida et al., Acta Neuropathol. 2013; López-González et al., in preparation). To dissect the pathogenicity of these disease molecules, we used fruit fly Drosophila and provided some important insights (Tran et al., Neuron 2015; Freibaum*, Lu* et al., Nature 2015; Yang et al., Acta Neur. 2015). In this proposal, we will continue to use C9ORF72 patients’ iPSCs-derived motor neurons as our experimental system together with some studies in fruit flies. We will build upon a large body of preliminary results we have already obtained, such as that iPSC-derived C9ORF72 motor neurons showed an age-dependent increase in the number of detrimental damages to the genome. These studies will greatly enhance our understanding of ALS pathogenic mechanisms and may identify components in the DNA damage pathway as potential therapeutic targets.

Mahasweta Girgenrath Ph.D.

**RG15**

**Utilizing natural history to identify optimal timeline for combinatorial therapy**

- $100,000.00 2/1/2016 1/31/2017 Year 1
- $100,000.00 2/1/2017 1/31/2018 Year 2

**Summary**

Laminin-deficient congenital muscular dystrophy (MDC1A) is the second most prevalent form of congenital muscular dystrophy (CMD). Children with this disease experience profound muscle weakness from a very young age and are never able to walk on their own. They typically die prematurely due to respiratory failure or failure to thrive. There remains no cure or treatment for MDC1A. Treatment with a single drug has been attempted but is only able to partially ameliorate some disease symptoms. This suggests a combinatorial treatment with more than one drug targeting multiple disease drivers may lead to better amelioration of the disease and result in increased life span and improved quality of life. We propose to use what we know about early disease progression in a mouse model of MDC1A to identify an ideal timeframe for dual treatment that will result in achieving maximal attenuation of disease symptoms to bring it closer to clinical trials.

MICHIGAN

**Ann Arbor - The Regents of the University of Michigan**

Asim Beg Ph.D.

**RG15**

**The Rac-GAP a2-chimaerin: a new target for motor neuron protection in ALS**

- $100,000.00 2/1/2016 1/31/2017 Year 1
- $100,000.00 2/1/2017 1/31/2018 Year 2
- $100,000.00 2/1/2018 1/31/2019 Year 3

**Summary**

Amyotrophic lateral sclerosis (ALS) is mostly a sporadic disease, but does have genetic origins. Regardless of cause, motor neuron degeneration is the unifying feature leading to paralysis and death. There are no treatments that halt disease onset or progression, highlighting the urgent need for therapies that positively modify disease course. Dismantling of neuromuscular junctions (NMJ), the site where a motor neuron axon communicates with a muscle cell, is an early pathological event that precedes motor neuron death. High expression of the repulsive axon guidance receptor EphA4 can initiate axonal retraction and NMJ degeneration in human ALS patients and animal models. Inhibiting proteins that relay destructive EphA4
signals is an attractive strategy to prevent these pathogenic events. We show that blocking a2-chimaerin, a critical EphA4 interacting protein, protects motor neurons from degeneration, delays disease onset and extends lifespan in ALS animal models. We hypothesize these beneficial effects are due to increased cytoskeletal health which prevents axonal retraction and NMJ degeneration. We will determine the precise cellular and molecular mechanisms underlying a2-chimaerin-dependent neuroprotection. Our findings will provide a first step toward decoding the molecular logic of EphA4-dependent motor neuron degeneration. This work will provide new insights into disease pathogenesis and may lead to new and more specific therapeutic strategies for treating ALS.

Andrew Lieberman M.D., Ph.D.

RG16 Modified antisense oligonucleotides to treat spinobulbar muscular atrophy

Summary: Spinal and bulbar muscular atrophy (SBMA) is a degenerative disorder of motor nerve cells and skeletal muscle caused by a mutation in the androgen receptor, the protein that binds male sex hormones. The disease causes progressive muscle weakness only in men, and no therapies are currently available. The objective of this application is to complete preclinical studies in a mouse model to establish the safety and efficacy of a new type of therapy to silence expression of the mutant gene. We will deliver this drug under the skin and target skeletal muscle; in fact, this new drug has been specially designed for efficient uptake by muscle. Our central hypothesis is that the enhanced targeting of muscle by this new drug will enable robust gene silencing at lower doses, thereby limiting off target toxicity while concurrently enhancing activity in a variety of disease-relevant muscles. These studies build upon our prior data pointing to significant benefits from this type of approach, and leverage the recent discovery of a chemical modification that increases drug uptake by skeletal muscle ~3-5-fold. We will use genetic, biochemical, histological and behavioral analyses to accomplish these goals. We will (1) establish the extent to which this modified drug triggers enhanced gene silencing and prevents disease onset in SBMA mice, and (2) determine effects of this drug in symptomatic SBMA mice. These studies are expected to provide essential efficacy data in a preclinical model.

MINNESOTA

Minneapolis - Regents of the University of Minnesota - Twin Cities

James M. Ervasti Ph.D.

RG Non-invasive biomarkers of defective mitochondrial metabolism in DMD

Summary: While several experimental therapies are in development for Duchenne muscular dystrophy (DMD), a significant obstacle for conducting clinical trials has been the lack of a simple and reliable method to measure therapeutic efficacy. To search for a molecular biomarker capable of monitoring disease progression, we measured the concentration of several hundred metabolites in urine from the mdx mouse model of DMD. Intriguingly, the concentration of Krebs cycle metabolites was significantly lower in the mdx mice as well as a small cohort of DMD patients. Since the Krebs cycle is necessary for producing energy in the form of ATP, our observation synergizes with previous work describing a global “energy-crisis” as a component of DMD pathology. We also have evidence that reduced Krebs cycle capacity may be an important mechanistic component of the skeletal muscle pathology associated with DMD. The goal of our project is to elucidate the role of Krebs cycle dysfunction in skeletal muscle pathology and to measure these metabolic changes in a large cohort of DMD patients in an effort to develop a non-invasive means of monitoring disease progression, which would improve our ability to conduct clinical trials for new DMD therapies.

Nam Chul Kim Ph.D.

DG15 Role of a ubiquitin ligase, UBE4B, in mutant VCP-mediated diseases

Summary: Mutations in Valosin-containing protein (VCP) underlie familial forms of amyotrophic lateral sclerosis and inclusion body myopathy. VCP functions as a ubiquitin-dependent segregase that extracts ubiquitinated targets from a complex structure, thus regulating many distinct cellular processes. The mechanism whereby mutations in VCP cause disease is unknown, no cure or effective treatment exists for patients. In order to
elucidate the disease causing mechanism and to identify putative therapeutic targets, we have generated a Drosophila model with mutant dVCP and performed genetic screening. Interestingly, we found the ubiquitin E3/E4 ligase, UBE4B, as a strong genetic modifier. RNAi knock-down of UBE4B strongly rescues degeneration of eyes and neurons caused by VCP mutation. We also have found that UBE4B binds more strongly to mutant VCP. Therefore, I hypothesize that mutant VCP’s toxicity is predominantly mediated through increased interaction with UBE4B and its ligase activity and that modulating this interaction may be a beneficial treatment strategy. In this project, I will confirm the results from Drosophila in a mammalian system and test whether inhibiting the enhanced interaction between UBE4B and mutant VCP could be a useful therapeutic strategy. I will identify common interactors and cellular pathways of VCP and UBE4B via interactome analysis by mass spectrometry.

Michael Kyba PhD

RG Determinants of self-renewal and differentiation of satellite cells

$100,000.00 8/1/2016 7/31/2017 Year 2

$100,000.00 8/1/2017 7/31/2018 Year 3

Summary Skeletal muscle is highly regenerative, thanks to a population of satellite cells, stem cells for skeletal muscle that differentiate into muscle fibers when necessary and self-renew for the lifetime of an organism. Our understanding of how satellite cells undertake decisions to proliferate, self-renew or differentiate is very limited. This is important because the ability to regenerate shows wide variation between individuals, and declines precipitously as muscular dystrophy advances. This proposal is focused on discovering and studying genes that regulate the regenerative potential of satellite cells, and will lead to a better understanding of skeletal muscle regeneration in disease states, and of the differences in muscle regenerative potential between individuals.

Joseph M Metzger Ph.D

RG16 Molecular basis of dystrophic cardiomyopathy

$100,000.00 8/1/2017 7/31/2018 Year 1

$100,000.00 8/1/2018 7/31/2019 Year 2

$100,000.00 8/1/2019 7/30/2020 Year 3

Summary The MDA has the ultimate goal of finding a cure for DMD. Despite great efforts there is no cure for DMD. In this context, it is reasonable to propose that an effective treatment that could prevent or even delay key aspects of DMD muscle disease would be the next best outcome in place of a cure. Ongoing genetic-based therapies, such as exon skipping and gene therapy, are advancing through clinical trials. These therapies involve a treatment in which a shortened dystrophin molecule is made by "deleting" regions of the gene. We have found, unexpectedly, that truncated dystrophin molecules can have markedly reduced stability in striated muscle in vivo as compared with normal full length dystrophin. We propose here a high precision truncated dystrophin peptide "titration" platform to directly access the in vivo stability of clinically relevant shortened dystrophin proteins in striated muscle. Outcome of this work is essential to define the key parameters of dystrophin dosing and function required for the ultimate success of on-going and future genetic-based clinical trials for DMD.

DeWayne Townsend D.V.M., Ph.D.

RG Hypoxia as a Modulator of Dystrophic Cardiomyopathy

$100,000.00 8/1/2016 7/31/2017 Year 2

$100,000.00 8/1/2017 7/31/2018 Year 3

Summary Duchenne muscular dystrophy (DMD) is a fatal disease resulting from a combination of respiratory and cardiac failure. Despite the importance of these two critical physiological systems, very little is known regarding how they may interact during the progression of DMD. We propose that decreases in oxygen, secondary to respiratory dysfunction, are particularly injurious to the dystrophic heart. The central hypothesis is that dystrophic muscle cells use oxygen less efficiently and have difficulty generating energy at low oxygen levels. We have shown that dystrophic mice subjected to reductions in oxygen develop a metabolic acidosis. This is a condition where the tissues of the body produce excess acid and is most likely associated with shifts to anaerobic metabolism (energy production without using oxygen). However, in highly metabolic tissues, such as the heart, anaerobic metabolism is unable to meet the energy demands. These energy starved cells are more susceptible to damage following even normally tolerated stresses. The presence of a significant role for hypoxia in the progression of dystrophic cardiomyopathy would have a direct impact on the decisions regarding when to initiate ventilatory support. The studies proposed here will assess the importance of hypoxia using both mouse models and experiments in DMD patients. It is hoped that by moving directly into the patient population that we can expedite our understanding of the role of hypoxia in the pathophysiology of DMD.
**Summary**

Spinal Muscular Atrophy (SMA) is the leading genetic cause of infantile death yet there currently is no effective treatment. The goal of this project is to deliver an optimized antisense oligonucleotide in combination with factors that address distinct functional pathways that are deficient in SMA. This work could provide evidence for a new combinatorial approach to SMA that would address a broad range of patient needs.

**St. Louis - Washington University in St.Louis**

Anne M Connolly M.D.

HCTG  Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys with DMD

<table>
<thead>
<tr>
<th>Year</th>
<th>Value</th>
<th>Start</th>
<th>End</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>.00</td>
<td>1/1/16</td>
<td>4/30/17</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td>5/1/17</td>
<td>10/1/17</td>
</tr>
</tbody>
</table>

**Summary**

While it has been known for many years that corticosteroid use benefits boys with DMD, most clinicians do not consider treating until after age 3 or 4 years of age. The primary reason for the delay is that daily corticosteroid use has many side effects including short stature, obesity, and osteoporosis. A recent randomized blinded study of weekend oral corticosteroid use over one year showed equal improvement in strength with fewer side effects, particularly as related to growth and cushingoid changes. We will test the efficacy of oral weekend corticosteroid use in infants and young boys with DMD who are under age 30 months. We have demonstrated that the Bayley-III Scales of Infant development shows that infants and young boys in this age group who are untreated decline in abilities when compared to their peers. Furthermore, the North Star Ambulatory Assessment which scores the ability to walk, run, and take steps shows scores that are lower than typically developing boys. Here, in this Phase 2 historically controlled trial, we will use these two measures and treat boys at five MDA-DMD centers.

Aaron DiAntonio M.D.,Ph.D.

RG  Mechanism of axon loss in congenital motor neuropathies

<table>
<thead>
<tr>
<th>Year</th>
<th>Value</th>
<th>Start</th>
<th>End</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>$100,000.00</td>
<td>8/1/16</td>
<td>7/31/17</td>
</tr>
<tr>
<td>3</td>
<td>$100,000.00</td>
<td>8/1/17</td>
<td>7/31/18</td>
</tr>
</tbody>
</table>

**Summary**

The nervous system controls muscle contraction via signals sent from motor neurons in the spinal cord to muscles throughout the body. These signals travel down axons, which are long, thin processes connecting the cell bodies of neurons to muscles. In peripheral neuropathies, damage or loss of these axons disrupts neural control of muscle contraction and can severely impair neuromuscular function. We wish to understand how damaged axons degenerate, in order to identify new therapies that will protect axons in patients with peripheral neuropathy. We have identified the protein Sarm1 as an essential component of the axonal degeneration program. It is necessary and sufficient to induce the degeneration of injured axons. Furthermore, Sarm1 function is evolutionarily conserved—it promotes axonal degeneration in both fruit flies and mice and, hence, likely serves a similar function in people. We will use powerful genetic tools available in the fruit fly to identify the genes that act in response to Sarm1 activation. We will search for genes that when inhibited can block the destructive consequences of Sarm1 activation and maintain healthy axons. Once we identify these genes, we will test whether they have a similar function in mammalian neurons. These genes and the proteins made by these genes will be new therapeutic targets whose inhibition could block axon degeneration and maintain healthy connections between motor neurons and muscles in peripheral neuropathies.

Timothy M Miller M.D.,Ph.D

RG16  Understanding RAN Dipeptide Size and Kinetics in c9orf72 ALS

<table>
<thead>
<tr>
<th>Year</th>
<th>Value</th>
<th>Start</th>
<th>End</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$94,287.00</td>
<td>8/1/17</td>
<td>7/31/18</td>
</tr>
<tr>
<td>2</td>
<td>$94,060.00</td>
<td>8/1/18</td>
<td>7/31/19</td>
</tr>
<tr>
<td>3</td>
<td>$94,070.00</td>
<td>8/1/19</td>
<td>7/31/20</td>
</tr>
</tbody>
</table>
Summary

The most common genetic cause of ALS is a hexanucleotide repeat expansion mutation in the c9orf72 gene, causing 30% of familial ALS and 5-10% of non-inherited ALS cases. This repeat expansion causes the accumulation of dipeptide repeat proteins (DPRs), which aggregate in human tissues and have been found to be toxic in cellular and animal models. However, pathological characteristics of the DPRs do not seem to correlate with clinical characteristics or degenerative severity in patients, making it challenging to determine whether these DPRs directly contribute to degeneration in human ALS. Thus, while DPRs are an attractive therapeutic target, there remains a missing link between promising cell/animal work and human disease. In this grant, we propose to further investigate aspects of DPRs to determine their significance to human disease using innovative methodologies. We will develop a novel way to understand DPR size in human tissues and cerebral spinal fluid (CSF) as well as a method to determine the turnover rate of DPRs in CSF of c9orf72 expansion carriers. The turnover rate of DPRs may correlate with disease measures and could help define when and how to apply therapeutics. We have successfully developed methods for kinetic analysis of other proteins such as SOD1 in ALS and tau in Alzheimer's disease. We are well-prepared to carry out these studies, which have important implications in the understanding and treatment of c9orf72 ALS.

Daniel Summers Ph.D.

DG Molecular Mechanisms of NAD+ Homeostasis in Peripheral Neurons

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$60,000.00</td>
<td>8/1/2016</td>
<td>7/31/2017</td>
<td>Year 2</td>
</tr>
<tr>
<td>$60,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Summary

Neuromuscular disorders such as Charcot-Marie Tooth diseases are caused by poor communication between muscles and the neurons in the peripheral nervous system that control muscle function. In these diseases, genes are activated that turn on a self-destructive program that eventually degrades neuron function and contact with the muscle. Identifying the genes responsible for neuronal degeneration and how they work will lead to new therapeutics. I am investigating how a gene called Sarm1 contributes to neuron destruction. Activating Sarm1 leads to the loss of a metabolite called NAD+ that is absolutely essential for neuron health and survival. My studies will address how Sarm1 degrades this metabolite and affects neuron health in disease models of Charcot-Marie Tooth disorders. The goal of my work is to identify new targets for therapeutic intervention in these devastating disorders.

Conrad Chris Weihl M.D., PhD.

RG16 Therapeutic modulation of chaperone function in LGMD1D

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>8/1/2016</td>
<td>7/31/2017</td>
<td>Year 1</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td>Year 2</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2018</td>
<td>7/31/2019</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Summary

Protein aggregates are present in age-associated degenerative disease, including debilitating myopathies and muscular dystrophies. They form when proteins misfold, self-assemble and elude degradation. Protein chaperones, or heat shock proteins (HSPs), protect against the toxic misfolding and aggregation of proteins. Hence, mutations or deficiencies in the chaperone network lead to disease. Recently, we found that DNAJB6, an HSP40 co-chaperone, is mutated in a dominantly inherited inclusion body myopathy (IBM) also named limb-girdle muscular dystrophy type 1D (LGMD1D) (1). LGMD1D is a progressive late onset muscular dystrophy. This proposal will understand the role of DNAJB6 mutants in a degenerative myopathy. The goals of this proposal are to explore novel therapeutics for LGMD1D.

Conrad Chris Weihl M.D., PhD.

CG Chaperone Dysfunction in Muscle Disease: Therapeutic Approaches

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$7,500.00</td>
<td>7/1/2017</td>
<td>7/31/2017</td>
<td>Year 1</td>
</tr>
</tbody>
</table>

Summary

We request support for an accepted ENMC meeting. ENMC covers funds for EU travelers but not US investigators. Funding for 5 investigators is requested. Protein chaperones and HSP pathway have emerged as tractable therapeutic targets in the treatment of many diseases (cancer, neurodegenerative diseases and now muscular dystrophies). One drug Arimoclomol is currently in clinical trials for ALS and sIBM. This drug appears to be safe and has an initial hint at therapeutic efficacy. Since many muscle disease have been identified in the past 5 years with mutations in many of these key chaperones, it is now essential to understand the common pathologic, clinical and pathomechanistic features that may predict similar treatment strategies. This workshop would allow different groups of researchers to sit together and define clear steps for trial readiness, biomarker assessment and common pathogenic targets. • To achieve a better understanding of muscle disease associated with mutations in molecular chaperones or “chaperonopathies” • To understand the pathogenic/pathologic overlap in “chaperonopathies”, muscular dystrophies and sIBM • Identify therapeutic targets, evaluate current preclinical models and translate existing and novel chaperone modulation therapies to muscle disease • Establish chaperone specific biomarkers for therapeutic trials and
define muscle diseases amenable to this pathway • Engage clinical, basic and translational researchers in chaperone associated disease

NEVADA

Reno - Board of Regents, NSHE, obo University of Nevada, Reno

Dean J. Burkin Ph.D.

RG16  Alpha7 integrin enhancing small molecule for Duchenne Muscular Dystrophy

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start</th>
<th>End</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td>Year 1</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2018</td>
<td>7/31/2019</td>
<td>Year 2</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2019</td>
<td>7/31/2020</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Summary
Duchenne muscular dystrophy (DMD) is a fatal muscle disease for which there is no cure and limited treatment options. DMD is caused by mutations in the dystrophin gene that results in a complete absence of the dystrophin protein. Dystrophin forms a scaffold which serves as a molecular glue that binds muscle cells together and transmits force during muscle contraction. Loss of dystrophin causes muscle fibers to be damaged which causes muscle weakness. A second molecular glue called the alpha7beta1 integrin is also present in muscle and studies have shown that increased levels of this second system can prevent disease progression. We have conducted a drug screen and identified a compound that increases the alpha7beta1 linkage system in muscle. This compound has an FDA approved analog and in this proposal we aim to test this in mouse models of DMD. Since this is already an FDA approved drug, a successful outcome of this project may more rapidly translate this as a new integrin-based therapy for DMD patients.

Peter Jones PhD

RG15  FSHD-like mice for therapeutic development and preclinical testing

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start</th>
<th>End</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>2/1/2016</td>
<td>1/31/2017</td>
<td>Year 1</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>2/1/2017</td>
<td>1/31/2018</td>
<td>Year 2</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>2/1/2018</td>
<td>1/31/2019</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Summary
A major impediment to developing ameliorative treatments for facioscapulohumeral muscular dystrophy (FSHD) is the lack of a viable, robust, and consistent phenotypic FSHD-like animal model. We have addressed this void by generating a novel transgenic mouse model based on the widely accepted model for FSHD being caused by increased expression of the DUX4 gene thereby causing a cascade of events leading to FSHD pathophysiology. Thus, the DUX4 mRNA, DUX4 protein and downstream targets are all potential targets for therapeutic development. We have successfully engineered lines of mice that contain the human DUX4 gene while maintaining its native human gene structure. Initial characterization of this mouse indicates that it is healthy and fertile in the absence of inducing DUX4 expression. Induction of DUX4 causes a muscular dystrophy-like phenotypes ranging from very mild to very severe. One can imagine that different disease courses may have different application for therapeutic testing. Therefore, here we will determine the precise conditions necessary to develop multiple screenable FSHD-like phenotypes in this mouse with varying courses of pathology. In addition, we will characterize the natural history of disease in the models. Successful completion of this project will provide the FSHD field with valuable tools for screening numerous classes of potential FSHD therapeutics aimed at DUX4 and its downstream targets and ultimately lead to ameliorative treatments for FSHD.

NEW JERSEY

Newark - Rutgers, The State University of New Jersey–RBHS–NJMS

Diego Fraidenraich Ph.D.

RG16  Aberrant connexin-43 production in muscular dystrophy

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start</th>
<th>End</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>8/1/2016</td>
<td>7/31/2017</td>
<td>Year 1</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td>Year 2</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2018</td>
<td>7/31/2019</td>
<td>Year 3</td>
</tr>
</tbody>
</table>

Summary
In muscular dystrophy it is not well understood why certain fibers are more susceptible to damage than others, or how necrosis spreads to neighboring fibers. Our long-term objective is to investigate the mechanisms of cell-cell communication leading to the expansion of damage in DMD. To achieve this goal, we have studied mdx mice with no dystrophin. We have also injected muscular dystrophy (mdx) embryonic stem cells (ESCs) into wild-type (WT) blastocysts to generate mdx/WT chimeras with reduced dosage of dystrophin. We have recently shown that Cx43, which communicates apposing cardiomyocytes via gap junction channels, plays a critical role in the onset of arrhythmias and lethality of muscular dystrophy mice under stress (Gonzalez et al., Nature Sci Rep, 2015). In preliminary studies for this proposal, we show that
connexin 43 (Cx43) is ectopically expressed in skeletal muscle fibers in DMD mouse and human. Because denervated fibers express Cx43 before becoming apoptotic/necrotic, we believe that the aberrant expression of Cx43 in dystrophic muscles potentiates the appearance of necrotic foci. In this study, we will determine whether genetic reduction in the Cx43 dose in mdx:Cx43(+/−) mice and in mdx/Cx43(+/−) chimeras attenuates the extent of necrotic damage and ameliorates disease. Because Cx43 is being considered as a target for important cardiac pathologies, the accomplishment of this proposal will help to elucidate unsuspected new roles for connexins in skeletal muscle.

NEW YORK

Binghamton - The Research Foundation of SUNY at Binghamton University

Yetrib Hathout Ph.D.

RG Development and validation of pharmacodynamic biomarkers for Duchenne.

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>8/1/2016</td>
<td>7/31/2017</td>
<td></td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td></td>
</tr>
</tbody>
</table>

Summary Currently there is no effective treatment for Duchenne muscular dystrophy (DMD) except use of corticosteroids that delays muscle inflammation for couple years but cannot cure the diseases and often results in adverse side effects. Recent and promising therapeutic strategies such as those aiming to restore the missing dystrophin protein and anti-inflammatory drugs with little to no side effects are being developed. However approval by a regulatory agency to test these drugs in DMD patients has been delayed due to the lack of tools to monitor drug efficacy. The only monitoring tool available today is the 6 min walk test, how far a patient can walk in 6 min. Unfortunately this test has proven to be challenging to preform by young children and also cannot be used for children who are about to lose or have lost ambulation. In this research project we propose to develop a panel of biomarkers detectable in blood circulation that are associated with DMD disease progression and, more importantly, can indicate if a drug is doing what it supposed to do or failed. We have already identified several biomarkers for DMD and we will test if these biomarkers will respond to new generation drugs for DMD.

New York - Columbia University Medical Center

Hiroshi Mitsumoto M.D.

RRG2 2015 Wings Over Wall Street - ALS Lipidomics and ALS COSMOS studies

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$70,191.95</td>
<td>1/1/2017</td>
<td>12/31/2017</td>
<td></td>
</tr>
</tbody>
</table>

Summary The MDA Wings Over Wall Street has generously supported extensive research at the Eleanor and Lou Gehrig MDA/ALS Research Center over the past 16 years. This year, we request support for lipidomic analyses in patients with ALS. There are more than 250 lipid species in the blood, and we found a highly unique pattern in ALS that may differentiate the disease from others. The project will confirm our discovery, and we will further determine if lipidic patterns evolve with disease progression. Further, we will continue to analyze extensive clinical, epidemiologic, and biomarker data derived from the ALS COSMOS project. With this year’s Wings’ grant, we will continue our vigorous research efforts to find the cause and cure for this dreaded disease.

Liza Pon Ph.D.

RG A newly identified congenital muscular dystrophy: mechanisms and interventions

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>8/1/2016</td>
<td>7/31/2017</td>
<td></td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td></td>
</tr>
</tbody>
</table>

Summary Congenital muscular dystrophy (CMD), one of the most frequent dystrophies of childhood, is characterized by neonatal muscle hypotonia, muscle weakness, stiff or frozen joints and delayed motor milestones. The focal point of these studies is CHKB CMD, a newly identified CMD in which patients exhibit generalized muscle wasting and weakness from early infancy with ambulatory delays and severe mental retardation. CHKB CMD patients can die as early as 2 years of age from cardiomyopathy. Currently, there is no cure for CHKB CMD. We will study the mechanism underlying CHKB CMD and possible therapeutic interventions.

New York - Joan & Sanford I. Weill Medical College of Cornell University

Marilena D'Aurelio Ph.D.

RG16 Intermediary metabolism biomarkers in mitochondrial myopathies

<table>
<thead>
<tr>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>8/1/2016</td>
<td>7/31/2017</td>
<td></td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2017</td>
<td>7/31/2018</td>
<td></td>
</tr>
<tr>
<td>$100,000.00</td>
<td>8/1/2018</td>
<td>7/31/2019</td>
<td></td>
</tr>
</tbody>
</table>
Mitochondrial diseases are heterogeneous genetic disorders caused by impairment of the system producing energy in mitochondria and manifest with severe myopathic and neurological features. Although the genetic defects are known, many aspects of the disease pathogenesis are yet to be elucidated. Amino acid metabolism is connected with glucose metabolism and the mitochondrial energy-generating system through the tricarboxylic acid (TCA) cycle. In muscle of patients with severe mitochondrial myopathy associated with Myoclonus Epilepsy and Ragged Red Fibers (MERRF) we find increased muscle protein breakdown and increased glutamate and alanine. Our hypothesis is that in mitochondrial disorders, increased utilization of glutamate into the TCA may affect amino acid metabolism and alter the homeostasis of essential metabolites in vital organs thus contributing to the pathogenesis of mitochondrial diseases. Interestingly, in Autosomal Dominant Optic Atrophy (ADOA) patients, a disease with milder myopathy, alanine is not increased, suggesting that specific metabolites, products of the amino acids metabolism could be used as biomarkers in mitochondrial diseases. We propose to quantify metabolites of 80 muscles and 30 sera from patients with different mitochondrial myopathies and controls. We will uncover altered pathway of the amino acid metabolism to be targeted by therapeutic metabolic supplementation and prognostic biomarkers for monitoring disease progression.

Giovanni Manfredi M.D., Ph.D.

RG15  
CHCHD10 in familial ALS

<table>
<thead>
<tr>
<th>Year</th>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year 1</td>
<td>$99,999.00</td>
<td>2/1/2016</td>
<td>1/31/2017</td>
</tr>
<tr>
<td>Year 2</td>
<td>$99,999.00</td>
<td>2/1/2017</td>
<td>1/31/2018</td>
</tr>
<tr>
<td>Year 3</td>
<td>$99,999.00</td>
<td>2/1/2018</td>
<td>1/31/2019</td>
</tr>
</tbody>
</table>

Amyotrophic lateral sclerosis (ALS) is a rapidly fatal neuromuscular degenerative disorder, affecting the motor neurons. It leads to paralysis and death in a short period of time and to date there are no cure or effective treatment available. There are several different genetic forms of ALS and the gene mutations responsible for the disease have been identified in almost 80% of the familial cases. Mitochondria are organelles crucial for energy metabolism in all cells, but neurons are particularly susceptible to mitochondrial dysfunction. Many lines of evidence point to mitochondria as targets of ALS disease mechanisms and very recently a new gene has been identified as causative of familial ALS, which encodes for a mitochondrial protein, CHCHD10. The function of the protein is unknown and the mechanisms of disease remain to be elucidated. Therefore, this application will take on the task of understanding how the protein works in mitochondria and how mutations cause neurodegeneration, using novel cellular and mouse disease models. The goal is to shed new light on the causes of ALS and specifically the involvement of mitochondria.

New York - Johns Hopkins University

Gabsang Lee Ph.D., D.V.M.

RG15  
Modeling Duchenne muscular dystrophy with hiPSCs and pharmacological rescue

<table>
<thead>
<tr>
<th>Year</th>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year 1</td>
<td>$100,000.00</td>
<td>2/1/2016</td>
<td>1/31/2017</td>
</tr>
<tr>
<td>Year 2</td>
<td>$100,000.00</td>
<td>2/1/2017</td>
<td>1/31/2018</td>
</tr>
<tr>
<td>Year 3</td>
<td>$100,000.00</td>
<td>2/1/2018</td>
<td>1/31/2019</td>
</tr>
</tbody>
</table>

Duchenne muscular dystrophy (DMD) is one of the most common muscular dystrophies. DMD is caused by mutations DYSTROPHIN and so far over 1,000 different sequence variations in the culprit gene (www.dmd.ml) have been known. Although several rodent, feline and canine models have provided DMD-related data on pathogenesis, the disease progression in the animals is somewhat different from that in human patients. Humanized DMD models carrying patient-specific DYSTROPHIN mutations will be complementary to current animal models of DMD, and one such example is DMD-specific human induced pluripotent stem cells (hiPSCs). Here, we propose to generate patient-specific myoblasts from DMD-specific hiPSC lines, followed by cellular/molecular characterization for better understanding of the pathogenesis, validating pharmacological and genetic intervention in vitro, and modeling microenvironments of DMD lesions receptive for healthy myoblasts. Our ‘DMD-in-a-dish’ model will be essential for tackling such a devastating muscular dystrophy.

New York - The Trustees of Columbia University in the City of New York.

Jacqueline Montes EdD

CG  
Spinal Muscular Atrophy: Evaluation and Management for the Rehabilitation Specia

<table>
<thead>
<tr>
<th>Year</th>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year 1</td>
<td>$10,000.00</td>
<td>10/20/2017</td>
<td>10/21/2017</td>
</tr>
</tbody>
</table>

Summary With the advent of disease modifying therapies along with additional therapies currently in development, there is an increased demand on community healthcare providers to evaluate and treat individuals with spinal muscular atrophy (SMA). This has prompted a need to develop an interprofessional network of
healthcare specialists, physicians, physical and occupational therapists and nurses, outside specialized centers, in the evaluation and management of individuals with SMA. This demand will continue to increase in the near future with promising therapeutic developments in genetically determined neuromuscular conditions. The purpose of this 1.5 day course is to (1) educate healthcare providers on the broad phenotypic spectrum of pediatric and adult SMA, the natural history of disease, recent updates to standards of care, standardized clinical outcome measures and the implications of approved and investigational therapies; and (2) to prepare clinicians, outside of specialized SMA centers, to manage rehabilitation care and administer and monitor progress using standardized SMA clinical assessments.

New York - Trustees of Columbia University in the City of New York Morningside

James Manley Ph.D.

RG15 Senataxin, mutated in ALS4, regulates autophagy

$99,528.00 2/1/2016 1/31/2017 Year 1
$100,000.00 2/1/2017 1/31/2018 Year 2
$99,917.00 2/1/2018 1/31/2019 Year 3

Summary

Neurological diseases are disorders of the brain, spinal cord and nerves that control the body. Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease and is caused by degeneration of motor neurons in the brain and spinal cord. The disease progression is usually extremely fast and ALS patients die in a course of 3 to 5 years after being diagnosed. We study a specific and unusual type of familial ALS, called ALS4. ALS4 begins in childhood or adolescence and has a slow rate of progression and does not affect patient's life span. However, like other ALS patients ALS4 patients suffer from progressive weakness of the limbs and face severe disabilities. Mutations in the gene encoding the protein Senataxin (SETX) are responsible for ALS4. Importantly, we found that the absence of SETX leads to a defect in the clearance of unwanted and defective components of the cells (a process called autophagy), what can lead to cell toxicity and ultimately cell death. Defects in autophagy have been reported in numerous neurological disorders that include Alzheimer's and Parkinson's diseases and ALS. Our studies are aimed at dissecting how SETX participates in autophagy regulation and importantly, how ALS4 mutations can affect this process. A fuller understanding of the molecular function of SETX in regulation of autophagy will lead to a better understanding of ALS, and ultimately to novel therapeutic approaches to prevent and treat the disease.

Rochester - University of Rochester

Douglas Anderson Ph.D.

DG15 Mitigating Muscular Dystrophy with a Calcium-regulatory Micropeptide

$60,000.00 2/1/2016 1/31/2017 Year 1
$60,000.00 2/1/2017 1/31/2018 Year 2
$60,000.00 2/1/2018 1/31/2019 Year 3

Summary

Defects in calcium handling are a hallmark of muscle diseases, including muscular dystrophies, that activate a series of pathological events that contribute to muscle weakness and damage. In contrast, restoring the normal movement of calcium can ameliorate muscle pathology and improve the performance of damaged muscles. Effective approaches to enhance calcium handling as a treatment for muscular dystrophies are currently unavailable, in part due to a lack of understanding about the molecular mechanisms that regulate calcium handling in skeletal muscle. We recently discovered a novel small membrane protein, called Myoregulin, that functions as a direct inhibitor of the calcium pump that controls muscle contractility. Genetic studies in mice have shown that Myoregulin is an important regulator of muscle performance, however, its role in mediating muscle disease is unknown. Recent preliminary studies have demonstrated that overexpression of Myoregulin alone is sufficient to induce a muscular dystrophy-like phenotype. This proposal aims to characterize the role of Myoregulin as a driver of muscle disease and as a potential therapeutic target for enhancing intracellular calcium handling as a treatment for muscular dystrophies.

Robert Griggs M.D.

HCTG FOR-DMD: Double-Blind Randomized Trial to Optimize Steroid Regimen in Duchenne MD

$.00 10/1/2016 9/30/2017 Year 4

Summary

This application requests funds for reimbursement for subject travel for an NIH-funded multicenter trial comparing long-term regimens of corticosteroids in boys with Duchenne muscular dystrophy (DMD). The corticosteroid prednisone is of established 18 months benefit to strength in DMD and another corticosteroid, deflazacort, may also be of benefit. Many corticosteroid regimens have been in use because of concerns regarding side effects and long-term risk/benefit, resulting in great variations in practice. This randomized controlled trial compares the 3 most widely used corticosteroid regimens to see whether both daily
prednisone and daily deflazacort will be of greater benefit in terms of function and parent satisfaction than intermittent prednisone. The trial is randomizing 300 boys in North American and Europe aged 4-7 years to 0.75 mg/kg/d prednisone; 0.9 mg/kg/d deflazacort; or 0.75 mg/kg/d prednisone for 10 days alternating with 10 days off. Participants will be recruited over a 2 year period and followed for at least 3 years. The protocol includes standardized regimens for treatment and prevention of bone, cardiac, respiratory, behavioral, and cushingoid complications of DMD and corticosteroids. The average subject and his parent/guardian will have to stay overnight near the site to complete all procedures at each visit. It would be unfair to ask families to bear this cost. Therefore this application requests funds to reimburse North American families.

Charles Thornton MD
CRNG
Myotonic Dystrophy Clinical Research Network

<table>
<thead>
<tr>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>$306,000.00</td>
<td>1/1/2017</td>
<td>12/31/2017</td>
</tr>
<tr>
<td>$306,000.00</td>
<td>1/1/2018</td>
<td>12/31/2018</td>
</tr>
</tbody>
</table>

Summary
The goal of this project is to support a Clinical Research Network for studies of myotonic dystrophy. Five centers are participating in the Network. The centers are distributed across the U.S. to maximize the opportunity for individuals with myotonic dystrophy to participate in research studies. Each center in the Network has a particular interest and expertise in clinical care and research on myotonic dystrophy. One of the main goals of the Network is to optimize the methods for testing of new treatments. Another goal is to understand genetic factors that explain the tremendous variability of how people are affected by myotonic dystrophy. The researchers in the Network will work together to standardize the methods for evaluating myotonic dystrophy, and determine the best ways to assess whether new medications are having a beneficial effect.

Charles Thornton MD
RRG2
2014 and 2015 All that Jazz Events - Genetic analysis of myotonic dystrophy

<table>
<thead>
<tr>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>$93,548.00</td>
<td>3/1/2017</td>
<td>2/28/2018</td>
</tr>
</tbody>
</table>

Summary
The goal of this project is to improve genetic testing for myotonic dystrophy and other genetic disorders that have expanded repeats in DNA.

Stony Brook - Research Foundation of the State University of New York
Aaron M Beedle Ph.D.

<table>
<thead>
<tr>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000.00</td>
<td>2/1/2017</td>
<td>1/31/2018</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>2/1/2018</td>
<td>1/31/2019</td>
</tr>
<tr>
<td>$100,000.00</td>
<td>2/1/2019</td>
<td>1/31/2020</td>
</tr>
</tbody>
</table>

Summary
Dystroglycan-related muscular dystrophies are caused by abnormal processing of the protein alpha-dystroglycan. The abnormal processing impairs alpha-dystroglycan function causing muscular dystrophy with variable involvement of the heart, brain and eyes. Dystroglycan-muscular dystrophies are caused by mutations in many different genes, making it difficult to develop gene therapy strategies because there are so many gene targets. Instead, this goal of this proposal is to test a pharmacological approach inhibiting a common intracellular pathway involving a protein called mTOR. Preclinical studies will be conducted to test the benefit of an mTOR inhibitor for improving muscle function, reducing pathology, and extending lifespan, while monitoring for potential drug adverse effects in mice with dystroglycan muscular dystrophy. A significant therapeutic benefit in these studies has the potential for rapid translation to the clinic.

NORTH CAROLINA
Charlotte - Carolinas HealthCare Foundation
Ibrahim Binalsheikh MD

<table>
<thead>
<tr>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>$242,636.65</td>
<td>1/1/2017</td>
<td>12/31/2017</td>
</tr>
</tbody>
</table>

Summary
The study is comprised of two parts. The first part is dedicated to discovering a gene therapy for patients with muscular dystrophy Type 2I that may cure or improve their muscle weakness. The second part focuses on observing the clinical evolution of patients with Limb Girdle Muscular Dystrophy over time and observing the variable symptoms and illnesses that they may develop. In addition, the pattern of weakness and its severity are also monitored.

OHIO
Columbus - Research Institute at Nationwide Children's Hospital
Scott Q. Harper Ph.D.

RG16 Therapeutic development for FSHD using a new DUX4-expressing knockin mouse

$100,000.00  2/1/2017  1/31/2018  Year 1
$100,000.00  2/1/2018  1/31/2019  Year 2
$100,000.00  2/1/2019  1/31/2020  Year 3

Summary No treatment exists for Facioscapulohumeral muscular dystrophy (FSHD). FSHD is caused by expression of the toxic DUX4 gene in muscle, and so strategies for treatments should focus on reducing or turning off DUX4. Before new treatments can be used in humans, they must first be tested in animal models to ensure that they (1) work and (2) are safe. In the case of FSHD, this would ideally mean having an animal model that expresses DUX4 and has diseased muscles, which could then be treated with an anti-DUX4 therapy. Although mice have been created that contain the DUX4 gene in their chromosomes, they unfortunately do not develop muscle disease or they die before birth. This fact represents a roadblock for therapy development. We have recently developed such a mouse, and are seeking funding to characterize it and use it for DUX4 inhibition therapy testing.

Columbus - The Ohio State University (OSU)
Arthur H.M. Burghes Ph.D.

RG Defining the information for precise genotype-phenotype correlation in SMA

$100,000.00  8/1/2016  1/31/2018  Year 2

Summary The severity of spinal muscular atrophy is determined by the number of intact SMN2 genes. Although assays have been developed that determine SMN2 copy number they do not indicate whether these genes are intact and can modify. We will develop assays that can determine the number of intact copies and improve prediction of SMA severity.

Columbus - The Ohio State University Research Foundation
Stephen James Kolb M.D., Ph.D.

HCTG Motor Function Test Reliability in NeuroNEXT Infant SMA Biomarker Study

$48,292.20  6/1/2016  5/31/2017  Year 3

Summary The SMA Biomarkers Study in the Immediate Postnatal Period of Development Clinical Study (NCT01736553), enrolling through the NINDS NeuroNEXT Clinical Trial Network, seeks to define the natural history of motor function and putative SMA molecular and physiological biomarkers in infants during the first two years of life. This prospective study, which includes healthy infants, is designed to provide reliable, definitive baseline measurements that may be used in the design of future SMA interventional trials. Ensuring the reliability and validity of outcome measures is essential to the success of this study. The 15 enrolling study sites are expected to enroll at a low rate and visits are not frequent. Thus, it is important that retraining occur on a regular basis to maintain reliability and maintain technical standardization of motor test administration. Retraining will include education, remediation when needed, monitoring and reliability assessment. In this proposal, we request supplementary funding to allow for training of the motor function test evaluators for the duration of the study. We propose bi-annual retesting of all evaluators using videos produced specifically for this study. We also propose annual in-person meetings for all evaluators for retraining and inter-rater reliability testing of live infants.

Columbus - The Research Institute at Nationwide Children’s Hospital
Kevin M Flanigan M.D.

CG Sixth Annual NCH/OSU/CORT Myology Course

$10,000.00  8/1/2017  12/31/2017  Year 1

Summary We propose a sixth annual intensive course directed toward clinically and laboratory trainees. The program has been developed by Dr. K. Flanigan, Prof of Pediatrics and Neurology at Nationwide Children’s Hospital, and Dr. D. Guttridge, Assoc. Prof of Cell Biology and Genetics at OSU. Faculty includes leaders in neuromuscular care and research, including members of the NCH/OSU Muscle Group as well as multiple external speakers. The target audience is international with requests for enrollment from programs in the US, Europe, and South America. Attendees will receive lectures on neuromuscular disease genetics and pathophysiology. Clinical trainees will receive didactic and hands-on training including neuromuscular pathology, methods of clinical assessment, and cardiorespiratory care. Laboratory trainees will have a wet lab experience with hands-on training in muscle cell culture, electrophysiology, and precursor cell isolation, among others. Each day will close with a keynote lecture. The program is designed to provide trainees with an integrated and intensive introduction to principles of neuromuscular disease. This course offers unique
opportunities for mentorship on career development. The attendees have adequate time to meet with course faculty to discuss both scientific and career development issues in an informal fashion. This, combined with our social mixer, provide opportunities for trainees to meet as peers and future collaborators.

Kathrin Christine Meyer PhD
DG15 Patient skin derived cells as a potential tool to subgroup ALS diversity
$60,000.00 2/1/2016 1/31/2017 Year 1
$60,000.00 2/1/2017 1/31/2018 Year 2
$60,000.00 2/1/2018 1/31/2019 Year 3

Summary The large variability of the disease course and progression in Amyotrophic Lateral Sclerosis (ALS) causes major problems in the understanding of disease mechanisms, as well as the design of clinical trials and the development of new therapeutics. Therefore, improved methods to sub-classify patients based on disease course or reactivity to potential therapeutics are urgently needed. The “direct conversion” is a new technique that allows fast and efficient generation of central nervous system (CNS) cell types involved in the ALS disease mechanism from skin of patients. In this project, we will evaluate whether these cells can be used for sub-classifying patients based on how they affect motoneurons that come in contact with them. Further, we can test how these patient cells react to different drugs or disease modifiers. Our preliminary data suggests that these patient cells display variable reactions to treatment. In this study, we will discern the molecular differences between patient derived CNS cells that either have a mild or severe effect on motoneuron death. Our project should help to find disease modifiers and novel potential therapeutic targets. In addition, we will evaluate the abundance of misfolded SOD1 in a large number patients that do not carry mutations in this protein. This will help to determine whether therapeutics targeting this protein would be suitable for a larger patient population.

Dayton - Wright State University
Mark Rich M.D., Ph.D.
RG15 Developing Therapy for Myotonia Congenita
$82,603.00 2/1/2016 1/31/2017 Year 1
$83,842.00 2/1/2017 1/31/2018 Year 2
$85,120.00 2/1/2018 1/31/2019 Year 3

Summary Myotonia congenita is an inherited muscle disease in which muscle is stiff because it contracts too much. The cause of stiffness is a genetic change in a protein that is involved in electrical signaling. Patients also have weakness when they begin to exercise. This weakness has never been understood. We have discovered the cause of the weakness to be a change in the electrical charge of the muscle fiber. This discovery suggests that in order to treat myotonia congenita we will need to fix both the stiffness and the weakness. While trying to figure out the cause of weakness we have discovered a novel electrical current in skeletal muscle. Our discovery has opened the door to development of new therapy that could greatly improve muscle function in patients. The goal of this proposal is to optimize therapy in the mouse model of myotonia congenita using newly available FDA approved medications, currently used for other conditions. Our results in mice will guide development a clinical trial in patients and hopefully lead to dramatic advances in treatment of myotonia congenita.

OKLAHOMA
Oklahoma City - Board of Regents of the University of Oklahoma, Health Sciences Center
Sanjay Bidichandani PhD
RG Epigenetic Silencing in Friedreich Ataxia
$100,000.00 8/1/2016 7/31/2017 Year 2
$100,000.00 8/1/2017 7/31/2018 Year 3

Summary People with Friedreich ataxia, the most common inherited ataxia, have an abnormally expanded GAA repeat sequence in both copies of their FXN gene. This leads to altered packaging of the FXN genes that turns off gene expression, and causes a deficiency of the essential protein frataxin. There is currently no approved therapy that can slow or stop the progression of disease. Our experiments are designed to determine the precise mechanism of this altered packaging in Friedreich ataxia, and to identify therapies to reverse it and restore normal FXN gene function.

PENNSYLVANIA
Philadelphia - The Trustees of the University of Pennsylvania
Tejvir S. Khurana MD, Ph.D.

RG16 Utrophin upregulation via let-7c SBO-mediated miRNA repression for DMD therapy
$80,000.00 2/1/2017 1/31/2018 Year 1
$80,000.00 2/1/2018 1/31/2019 Year 2
$80,000.00 2/1/2019 1/31/2020 Year 3

Summary Utrophin is highly related to the dystrophin gene. It is of great therapeutic interest since increasing its production in muscles can compensate for the lack of dystrophin in animal models of DMD. We have found that utrophin is in a state of repression and that a class of molecules called microRNA's (miRNAs) cause the repression. We will develop site-blocking oligo-based methods to repress the micro RNA let-7c repressor, in order to achieve Utrophin upregulation. These approaches will be tested in the mdx mouse model of DMD.

Steven S Scherer M.D., Ph.D.

CG 2017 Peripheral Nerve Society Meeting
$5,000.00 7/1/2017 7/30/2017 Year 1

Summary The Peripheral Nerve Society (PNS) is an international organization of physicians and scientists working together to develop and provide the best treatments for people who have peripheral nerve diseases, including Charcot-Marie-Tooth disease (CMT). Traditionally, the PNS has held a biennial meeting that alternates between North America and Europe, and the CMT meeting has been held directly after the PNS meeting since 2011. After 2017, the PNS will be an annual meeting with the same format. The 2017 PNS Biennial Meeting will be held in Sitges, Spain, July 8-12. This will be the first PNS meeting that will fully integrate the CMT meeting into its agenda. The traditional topics of past CMT meetings - “nerve biology” and CMT (including therapy) - will be one-half of the 2017 PNS meeting. The PNS board, along with the CMT scientists and clinicians, made this change for those who attend both, CMT and PNS, meetings. The back-to-back PNS-CMT meeting was too long. We also hope the new format will benefit CMT meeting attendees to a “larger view” of neuropathy and its treatments. The meeting’s objective remains the same - to bring together leading clinical and basic scientists as well as young investigators from around the world to share the most recent data relevant to the development of rational treatments for CMT. The MDA supports the research of many investigators who attend this meeting, and, if the past predicts the future, many of the future leaders in CMT are likely to attend.

Philadelphia - Thomas Jefferson University

Angelo C Lepore Ph.D.

RG Toward therapeutic intervention in ALS: role of ephrin signaling in astrocytes
$100,000.00 8/1/2016 7/31/2017 Year 2
$100,000.00 8/1/2017 7/31/2018 Year 3

Summary ALS is a devastating condition characterized by motor neuron (MN) loss in brain and spinal cord. Nevertheless, studies in ALS animal models and with patient tissues suggest that cellular abnormalities are not limited to MNs. In particular, astrocytes play a key role in ALS progression. However, the astrocyte mechanisms involved in ALS pathogenesis remain largely not understood, hampering development of effective therapies for targeting this cell population and for treating disease. The Eph and ephrin family of molecules plays a number of critical roles in the CNS. A recent finding demonstrated that expression of the Eph receptor, EphA4, in MNs significantly contributes to MN degeneration and overall disease pathogenesis in several ALS animal models and in human disease. EphA4 can be stimulated by binding to ephrin-B ligands, including ephrin-B2. We find pronounced ephrin-B2 up-regulation selectively in astrocytes in areas of MN loss in human ALS spinal cord and in SOD1-G93A mice, the most widely studied ALS animal model. Excitingly, we also find that reducing ephrin-B2 in spinal cord astrocytes prolongs disease in SOD1-G93A mice. These findings suggest that ephrin-B2 is (1) the ligand for pathogenic actions of EphA4, (2) a signaling mechanism underlying astrocyte pathogenicity in ALS, and (3) a promising treatment target. In this project, we will test the hypothesis that abnormal expression of ephrin-B2 in spinal cord astrocytes is a pathogenic mechanism in ALS.

Diane E. Merry Ph.D.

RG Targeting AR toxicity in SBMA through SIRT1 activation
$100,000.00 8/1/2016 7/31/2017 Year 2
$100,000.00 8/1/2017 7/31/2018 Year 3

Summary Many neurodegenerative diseases result from protein misfolding and accumulation due to a variety of genetic or environmental causes. Spinal and bulbar muscular atrophy (SBMA) is one such disease; it is an inherited, adult-onset, neuromuscular disease that is caused by the expansion of a polyglutamine tract...
within the androgen receptor (AR) and is related mechanistically to other neurodegenerative diseases caused by polyglutamine expansion. An important feature of SBMA is that its onset and progression are dependent on androgen binding by the mutant receptor. Our studies of mouse and cell models of SBMA that reproduce the androgen- and polyglutamine-dependent nuclear AR aggregation seen in patients, as well as its toxicity, revealed that the mutant AR must be modified by the addition of acetyl groups for its aggregation and toxicity. Moreover, the deacetylase SIRT1 is strongly neuroprotective in cell models of SBMA and this neuroprotection largely depends upon its ability to deacetylate the mutant AR. Here we will investigate the therapeutic potential of activating SIRT1 with small molecule activators. We will build on our preliminary findings that one of the compounds tested to date leads to decreased AR acetylation concomitant with decreased mutant AR aggregation and DHT-dependent toxicity. We anticipate that these studies will reveal new and powerful opportunities for therapeutic development in SBMA.

Davide Trotti Ph.D.

RG Molecular mechanisms of toxicity of the ALS/FTD-linked C9ORF72 gene.

$100,000.00 8/1/2016 7/31/2017 Year 2

$100,000.00 8/1/2017 7/31/2018 Year 3

Summary The discovery of aberrantly expanded repeat sequences in C9ORF72 gene is of great importance for the field of ALS research because it accounts for a larger proportion of familial and sporadic ALS cases than SOD1. This discovery therefore represents an opportunity to develop different and more impactful therapeutic approaches. Nevertheless, we lack knowledge of both the normal function of the C9ORF72 protein and the potential toxic effect of its aberrant mutations. Our recent work revealed that C9ORF72 neurotoxicity could be due to accumulation of aberrant C9ORF72-derived dipeptides. We recently found that a particular class of these proteins, the arginine-rich dipeptides, are potently toxic to motor and cortical neurons, that is the cell types that are affected in ALS/FTD. Another class of protein dipeptides generated from the C9ORF72 mutated gene, the glycine-alanine dipeptides, also triggered disease-relevant phenotypic changes in neurons, although they did not manifest short term intrinsic toxicity. More importantly, these aberrant proteins were reported in human induced motor neurons and postmortem spinal cord tissues obtained from C9ORF72 ALS and ALS/FTD patient autopsies, suggestive of their relevance to the human disease. In this study, we propose to investigate the mechanisms by which Proline-arginine exert their neurotoxicity and how the glycine-alanine proteins trigger dysfunction in neurons.

Pittsburgh - University of Pittsburgh

Paula Clemens M.D.

RG15 CINRG Becker Natural History Study - Travel Funding

$8,470.00 11/1/2016 10/31/2017 Year 2

$8,470.00 11/1/2017 10/31/2018 Year 3

Summary This proposal is to assist with travel and lodging costs for individuals with Becker Muscular Dystrophy participating in the ongoing study Becker Muscular Dystrophy – A Natural History Study to Predict Efficacy of Exon Skipping.

Christi L Kolarcik Ph.D.

DG16 Motor system connectivity influences in amyotrophic lateral sclerosis

$60,000.00 8/1/2016 7/31/2017 Year 1

$60,000.00 8/1/2017 7/31/2018 Year 2

$60,000.00 8/1/2018 7/31/2019 Year 3

Summary Communication between neurons and muscles occurs at synaptic connections which are often compromised in neuromuscular disease. Multiple hypotheses on where connections breakdown exist for amyotrophic lateral sclerosis (ALS). Do the earliest changes occur at the spinal motor neuron or the cortical level? How do disruptions in axonal transport contribute? Underlying these potential mechanisms is the neural circuitry which ultimately mediates the pathological process. This proposal will unravel the synaptic connections to motor neurons innervating affected muscles and determine how these change in ALS. Our hypothesis is that synaptic inputs to muscles affected in ALS will change with disease progression; these inputs will enable us to predict disease spread through the motor system. First, we will map the neural circuitry that controls the motor neurons innervating two hindlimb muscles in the mouse using transneuronal viral tracers. Both fast- and slow-twitch muscles will be included to identify muscle fiber/motor neuron-type specific changes. By defining the direct and more elaborate multi-synaptic pathways, we can determine how and when synaptic connections are affected as ALS progresses. We will investigate pre-symptomatic, denervation, symptom onset and end-stage disease phases. The time course of synaptic connectivity changes and transport deficits will be elucidated, providing insights into mechanisms underlying degeneration and leading to targeted therapeutic options.
Summary
ALS is a devastating motor neuron disease for which currently no effective therapies are available. We propose to identify drugs that can suppress symptoms associated with ALS.

Araya Puwanant M.D.

Sub-regional Body Composition and Clinical Endpoints in Myotonic Dystrophy

Summary
Myotonic dystrophy is the most prevalent form of muscular dystrophy in adults, characterized by progressive muscle weakness, muscle stiffness, and multi-organ involvement. This condition causes progressive disability and significant burden for affected individuals and caregivers. In recent years there has been significant progress in developing specific treatment for this condition. This project will facilitate therapeutic development by identifying practical and reliable endpoints for progressive muscle weakness and wasting in patients with myotonic dystrophy.

TEXAS
Dallas - UT Southwestern Medical Center

Ronald Haller M.D.

Impaired Oxidative Capacity in McArdle Disease: Causes and Treatment.

Summary
This study will investigate the cause of impaired muscle oxidative metabolism when muscle glycogen metabolism is blocked in McArdle disease and will determine the ability of triptanoin to correct the oxidative defect.

Houston - Baylor College of Medicine

Susan Hamilton Ph.D.

Molecular Mechanisms and New Interventions for Central Core Disease

Summary
Central Core Disease (CCD) is associated with mutations in the gene for the skeletal muscle Ca2+ release channel, RyR1. Currently there are no treatments for CCD. RyR1 is an extremely large protein and mutations in different locations within RyR1 have very different functional outcomes. Using two mouse models of CCD (Y522S and I4898T mutations), we show that while both mutations produce the muscle weakness characteristic of CCD, the mechanisms that lead to the muscle weakness are very different. We propose that therapeutic interventions for these two types of CCD will also need to be different. To test this hypothesis, we will test the efficacy of three interventions (identified in our laboratory as having the potential to treat CCD) in the two CCD mouse models to determine if different interventions work better in one type of CCD mouse than in the other. Since the three drugs are already either approved for use in humans or currently in clinical trials for other diseases, these studies will lay the groundwork for rapid development of therapeutic interventions for CCD.

James Lupski M.D., Ph.D., D.Sc. (hon)

Enhancing molecular diagnostics for unsolved neuromuscular disease cases.

Summary
Currently there are no treatments for CCD. RyR1 is an extremely large protein and mutations in different locations within RyR1 have very different functional outcomes. Using two mouse models of CCD (Y522S and I4898T mutations), we show that while both mutations produce the muscle weakness characteristic of CCD, the mechanisms that lead to the muscle weakness are very different. We propose that therapeutic interventions for these two types of CCD will also need to be different. To test this hypothesis, we will test the efficacy of three interventions (identified in our laboratory as having the potential to treat CCD) in the two CCD mouse models to determine if different interventions work better in one type of CCD mouse than in the other. Since the three drugs are already either approved for use in humans or currently in clinical trials for other diseases, these studies will lay the groundwork for rapid development of therapeutic interventions for CCD.
Determining genetic diagnoses in neuromuscular diseases (NMDs) are particularly difficult due to the large number of disease-causing genes and significant overlap in clinical symptoms between patients. Our proposal aims to advance molecular diagnostics for NMD patients that remain undiagnosed after clinical diagnostic whole exome sequencing (WES) and enhance discovery of novel disease genes. We aim to first comprehensively re-analyze clinical exome data in a research setting to confirm that a diagnosis has not been missed. Our next aim is to perform exome sequencing for the patient’s parents and/or other family members. This will help us find spontaneous or de novo mutations and novel genes associated with NMDs. For cases that remain unsolved, we will then carry out RNA sequencing from affected tissue, if available. The advantage of RNA sequencing from muscle tissue is that it can provide direct evidence of the functional impact of a mutation. We also propose whole genome sequencing (WGS) for cases where tissue is not available, as with decreasing sequencing costs, it is important to test whether WGS should replace WES in the clinic. Obtaining a molecular diagnosis is key for patients and families with NMDs as it affects family planning decisions, disease management, and participation in disease-specific registries and clinical trials.

KE MA MD, PhD

RG15  The Therapeutic Potential of Circadian Clock Modulators in Muscular Dystrophies
$100,000.00  2/1/2016  1/31/2017  Year 1
$100,000.00  2/1/2017  1/31/2018  Year 2
$100,000.00  2/1/2018  1/31/2019  Year 3

Summary Duchenne Muscular Dystrophy (DMD) is characterized by progressive muscle wasting and functional decline due to repeated cycles of degeneration and regeneration. Effective means to maintain critical muscle mass ameliorates muscle dystrophy and greatly improve survival of patients with DMD. Recently studies have demonstrated that circadian clock regulators play important roles in maintaining muscle mass and proper function. We found that Rev-erba, negative regulator of the clock, inhibits muscle cell proliferation, differentiation and muscle regeneration. As Rev-erba is a “druggable” ligand-modulated nuclear receptor, we will test whether inhibiting this protein by its specific antagonist, SR8278, can augment muscle regenerative abilities to improve muscle dystrophy in an animal model of DMD. These studies will determine the potential therapeutic applications of a Rev-erba inhibitor as a new ameliorative strategy to treat patients with muscular dystrophies.

Lubbock - Texas Tech University Health Sciences Center
Laxman D. Gangwani Ph.D.

RG16  Pharmacological inhibition of JNK for the treatment of spinal muscular atrophy
$93,500.00  2/1/2017  1/31/2018  Year 1
$93,500.00  2/1/2018  1/31/2019  Year 2
$93,500.00  2/1/2019  1/31/2020  Year 3

Summary Spinal muscular atrophy (SMA) is caused by the low levels of the survival motor neuron (SMN) protein and is characterized by degeneration of spinal motor neurons. Reduction in degeneration of neurons has been shown to slow the progression of SMA disease. Treatments to prevent or slow neurodegeneration are unavailable. Recently, we have shown that the c-Jun NH2-terminal kinase (JNK) pathway mediates neurodegeneration in SMA. The neuron-specific isoform JNK3 is required for neurodegeneration in SMA. We have validated JNK3 as a therapeutic target using SMA mice. Genetic inhibition of JNK in vivo by knockout of the Jnk3 gene results in improvement of SMA phenotype. JNK3-deficiency provides neuroprotection, reduces muscle degeneration, improve muscle growth, motor function and overall growth and increases lifespan of SMA mice that shows a systemic improvement of SMA phenotype. We propose to test the pharmacological inhibition of JNK for the treatment of SMA using JNK inhibitors in SMA mouse model.

UTAH
Salt Lake City - University of Utah
Nicholas Johnson M.D.

HCTG  Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy
$199,900.00  12/1/2016  12/1/2017  Year 1
$199,539.00  12/2/2017  12/1/2018  Year 2
$198,909.00  12/2/2018  12/1/2019  Year 3

Summary Congenital myotonic dystrophy is the most severe form of myotonic dystrophy type-1. This pediatric disorder causes severe disability throughout childhood. Currently, there are no available treatments for congenital myotonic dystrophy. In this project, we will develop meaningful clinical endpoints in congenital myotonic dystrophy to allow these children to participate in potential clinical trials. Children with congenital
myotonic dystrophy will have measurements of strength, cognition, and quality of life measured over the course of years. Measurements of the changes within the muscle will be used to see how the disease progresses over time. We will find the measurements that would be best used in a clinical trial. This is a necessary step to taking developing therapies into this patient population. The long-term goal is to reduce the disability for children with this disease.

**VIRGINIA**

Richmond - Virginia Commonwealth University

Montserrat Samso Ph.D

<table>
<thead>
<tr>
<th>RG</th>
<th>Structural Analysis of RyR1 with Central Core Disease Mutations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$100,000.00 8/1/2016 7/31/2017 Year 2</td>
</tr>
<tr>
<td></td>
<td>$100,000.00 8/1/2017 7/31/2018 Year 3</td>
</tr>
</tbody>
</table>

**Summary**

This project employs cryo electron microscopy to get accurate 3D renderings of the ryanodine receptor (RyR), a calcium channel important for contraction of the voluntary muscles. These 3D renderings will enable understanding how this channel works normally and how abnormal function results in central core disease. This will be combined by measurement of the function of this channel in live cells. These methods will be then used to evaluate novel agents designed to correct RyR malfunction that could be used as a potential new therapy for central core disease.

**WASHINGTON**

Seattle - University of Washington

Joel R. Chamberlain Ph.D.

<table>
<thead>
<tr>
<th>RG16</th>
<th>DUX4 protein phenotypic effects in FSHD biopsies and in a mouse model of FSHD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$100,000.00 8/1/2016 7/31/2017 Year 1</td>
</tr>
<tr>
<td></td>
<td>$100,000.00 8/1/2017 7/31/2018 Year 2</td>
</tr>
<tr>
<td></td>
<td>$100,000.00 8/1/2018 7/31/2019 Year 3</td>
</tr>
</tbody>
</table>

**Summary**

A roadblock in understanding the disease mechanism of FSHD has been the lack of a mouse model that recapitulates the muscle phenotypic changes associated with the disease. The sensitivity of muscle to the effects of DUX4 expression has hampered our ability to develop an animal model of FSHD that could give us key information about how the genetic changes lead to muscle weakness and potentially provide us points of intervention for therapy development. To address this problem we have developed a postnatal mouse model of FSHD based on muscle low-level expression of human DUX4 from the DUX4 promoter. DUX4 mice share muscle phenotypic features with human FSHD muscle that become more pronounced over time. This application will describe key advancements in our understanding of the effects of DUX4 protein expression, including the first localization of DUX4 protein in muscle and its physical association with muscle damage in both mouse and human tissue. We propose to use the mouse model and tools developed to characterize the origin of DUX4 protein expression and interrogate the molecular, biochemical, and functional changes in the DUX4 expressing mouse. In addition to linking expression of DUX4 protein to phenotypic changes in FSHD muscle, we will use what is learned from the mouse model characterization to guide our analyses of precious human biopsy samples and to inform testing of available and new potential therapies in animal models of disease.

Donghoon Lee Ph.D.

<table>
<thead>
<tr>
<th>RG</th>
<th>Magnetic Resonance Biomarkers for Effective Treatments for Muscular Dystrophy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$100,000.00 8/1/2016 7/31/2017 Year 2</td>
</tr>
<tr>
<td></td>
<td>$100,000.00 8/1/2017 7/31/2018 Year 3</td>
</tr>
</tbody>
</table>

**Summary**

The goal of this project is to develop noninvasive magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) biomarkers that identify underlying tissue and cellular events associated with degeneration and regeneration processes in muscular dystrophy. Clinical assessments of muscular dystrophy routinely involve genetic, physiological, biochemical and histopathological methods, largely by surgical biopsy. Although they provide key information of muscle dysfunction, these methods are limited by their narrow sampling regions of interest and invasive nature of the procedure. We developed multi-parametric magnetic resonance (MR) approaches that extended evidence that MR can significantly facilitate noninvasive diagnosis and monitoring of muscle dysfunction. MRI based on changes in T2 weighted (T2w) imaging is commonly used to identify regions of pathology in muscle because of their sensitivity to a wide range of mechanisms. However, the T2w MRI alone is unable to identify specific cellular processes in the affected areas. Our new MR tools can quantitatively monitor muscle degeneration and regeneration processes in muscular dystrophy. In this project, a group of MR tools will be devised that identify specific
markers for tissue and cellular changes with the disease progression and therapeutic treatments for muscular dystrophy. We will monitor the disease progression and identify biomarkers useful for effective monitoring of the therapy responses.